CRL Charles River Laboratories International Inc

---

---

---

---

---

---

---

---

---

The accompanying condensed consolidated financial statements are unaudited and have been prepared by Charles River Laboratories International, Inc. (the Company) in accordance with accounting principles generally accepted in the United States (U.S. GAAP) and pursuant to the rules and regulations of the Securities and Exchange Commission (SEC). The year-end condensed consolidated balance sheet data was derived from the Company’s audited consolidated financial statements, but does not include all disclosures required by U.S. GAAP. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K for fiscal year 2023 as filed with the SEC on February 14, 2024. Certain reclassifications of prior year amounts have been made to conform to the current year presentation. The unaudited condensed consolidated financial statements, in the opinion of management, reflect all normal and recurring adjustments necessary for a fair statement of the Company’s financial position and results of operations.

Use of Estimates

The preparation of unaudited condensed consolidated financial statements in accordance with U.S. GAAP requires that the Company make estimates and judgments that may affect the reported amounts of assets, liabilities, revenues, expenses and related disclosure of contingent assets and liabilities. On an on-going basis, the Company evaluates its estimates, judgments, and methodologies. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ from these estimates under different assumptions or conditions. Changes in estimates are reflected in reported results in the period in which they become known.

Newly Issued Accounting Pronouncements

In November 2023, the FASB issued ASU 2023-07, “Improvements to Reportable Segment Disclosures (Topic 280)”. ASU 2023-07 modifies reportable segment disclosure requirements, primarily through enhanced disclosures about segment expenses categorized as significant or regularly provided to the Chief Operating Decision Maker (CODM). In addition, the amendments enhance interim disclosure requirements, clarify circumstances in which an entity can disclose multiple segment measures of profit or loss, and contain other disclosure requirements. The purpose of the amendments is to enable investors to better understand an entity’s overall performance and assess potential future cash flows. This ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted and the amendments in this update are required to be applied on a retrospective basis. The Company is currently evaluating the impact this new standard will have on the related disclosures in the annual consolidated financial statements, but does not believe there will be a material impact.

In December 2023, the FASB issued ASU 2023-09, “Improvements to Income Tax Disclosures (Topic 740)”. ASU 2023-09 requires enhanced disclosures on income taxes paid, adds disaggregation of continuing operations before income taxes between foreign and domestic earnings and defines specific categories for the reconciliation of jurisdictional tax rate to effective tax rate. This ASU is effective for fiscal years beginning after December 15, 2024, and can be applied on a prospective basis. The Company is currently evaluating the impact this new standard will have on the related disclosures on the consolidated financial statements.

Summary of Significant Accounting Policies

The Company’s significant accounting policies are described in Note 1, “Description of Business and Summary of Significant Accounting Policies” in the Company’s Annual Report on Form 10-K for fiscal year 2023 as filed with the SEC on February 14, 2024.

Consolidation

The Company’s unaudited condensed consolidated financial statements reflect its financial statements and those of its subsidiaries in which the Company holds a controlling financial interest. For consolidated entities in which the Company owns or is exposed to less than 100% of the economics, the Company records net income (loss) attributable to noncontrolling interests in its unaudited condensed consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Redeemable noncontrolling interests, where the noncontrolling interest holders have the ability to require the Company to purchase the remaining interests, are classified in the mezzanine section of the unaudited condensed consolidated balance sheets, which is presented above the equity section and below liabilities. Intercompany balances and transactions are eliminated in consolidation.

The Company’s fiscal year is typically based on 52-weeks, with each quarter composed of 13 weeks ending on the last Saturday on, or closest to, March 31, June 30, September 30, and December 31. A 53rd week in the fourth quarter of the fiscal year is occasionally necessary to align with a December 31 calendar year-end.

---

Segment Reporting

The Company reports its results in three reportable segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).

The Company’s RMS reportable segment includes the Research Models, Research Model Services, and Cell Solutions businesses. Research Models includes the commercial production and sale of small research models, as well as the supply of large research models. Research Model Services includes: Insourcing Solutions (IS), which provides colony management of clients’ research operations (including recruitment, training, staffing, and management services) within the clients’ facilities and utilizing the Charles River Accelerator and Development Lab (CRADL™) offering, which provides vivarium space to clients, Genetically Engineered Models and Services (GEMS), which performs contract breeding and other services associated with genetically engineered models, and Research Animal Diagnostic Services (RADS), which provides health monitoring and diagnostics services related to research models; and Cell Solutions, which supplies controlled, consistent, customized primary cells and blood components derived from normal and mobilized peripheral blood and bone marrow.

The Company’s DSA reportable segment includes two businesses: Discovery Services and Safety Assessment. The Company provides regulated and non-regulated DSA services to support the research, development, and regulatory-required safety testing of potential new drugs, including therapeutic discovery and optimization plus in vitro and in vivo studies, laboratory support services, and strategic non-clinical consulting and program management to support product development.

Fiscal 2023 Acquisition

Noveprim Group

On November 30, 2023, the Company completed the acquisition of an additional 41% equity interest of Noveprim Group (Noveprim), a leading supplier of non-human primates (NHPs) located in Mauritius, resulting in a 90% controlling interest. The Company had previously acquired a 49% equity interest in 2022 for $90.0 million plus additional contingent payments up to $5.0 million based on future performance. The total consideration allocable to the Noveprim acquisition is $392.4 million, which includes $144.6 million additional cash paid for the 41% equity interest, elimination of historical activity and intercompany balances of $209.5 million which includes a remeasurement gain on the 49% equity investment of $113.0 million, contingent consideration of $33.3 million, deferred purchase price of $12.0 million payable from 2024 through 2027, offset by estimated post-closing adjustments for working capital of $7.0 million. The purchase price reflected a preliminary agreement with seller on working capital and debt, which was adjusted from $13.8 million to $7.0 million during the quarter ended June 29, 2024. As a result of measurement period adjustments to the purchase price, goodwill and remeasurement gains on the previous 49% equity investment for the quarter ended June 29, 2024, were increased by $17.6 million and $9.8 million, respectively. The contingent consideration fair value is estimated using a Monte Carlo Simulation model and the maximum contingent contractual payments are up to $55.0 million based on future performance and milestone achievements in fiscal years 2023 through 2025. The Company has the call option right to purchase the remaining 10% equity interest up until one month after the sixth anniversary of closing the 41% equity interest. On the first anniversary of the expiration of the call option, a 12-month put option will be triggered giving the seller the right to require the Company to acquire the remaining shares of the seller. The redemption price for the call/put is fixed and ranges from $47.0 million to $54.0 million depending on when exercised. The noncontrolling interest is classified as a redeemable noncontrolling interest in the mezzanine section of the unaudited condensed consolidated balance sheet. The acquisition was funded through a combination of available cash and proceeds from the Company’s Credit Facility. This business is reported as part of the Company’s DSA reportable segment for NHPs vertically integrated into the DSA supply chain and the RMS reportable segment for those NHPs sold to third party customers. The Company incurred transaction and integration costs in connection with the acquisition of $0.7 million and $1.4 million for the three months ended June 29, 2024 and July 1, 2023, respectively, which was primarily included in Selling, general and administrative expenses within the unaudited condensed consolidated statements of income. The Company incurred transaction and integration costs in connection with the acquisition of $0.9 million and $2.2 million for six months ended June 29, 2024 and July 1, 2023, respectively, which was primarily included in Selling, general and administrative expenses within the unaudited condensed consolidated statements of income.

---

SAMDI Tech, Inc.

On January 27, 2023, the Company acquired SAMDI Tech, Inc., (SAMDI), a leading provider of high-quality, label-free high-throughput screening (HTS) solutions for drug discovery research. The acquisition of SAMDI will provide clients with seamless access to the premier, label-free HTS MS platform and create a comprehensive, library of drug discovery solutions. The purchase price of SAMDI was $62.8 million, net of $0.4 million in cash, inclusive of a 20% strategic equity interest previously owned by the Company of $12.6 million. The acquisition was funded through a combination of available cash and proceeds from the Company’s Credit Facility. This business is reported as part of the Company’s DSA reportable segment. No significant transaction and integration costs were incurred with the acquisition for the three and six months ended June 29, 2024. The Company incurred transaction and integration costs in connection with the acquisition of $0.3 million for the three and six months ended July 1, 2023, respectively, which was primarily included in Selling, general and administrative expenses within the unaudited condensed consolidated statements of income.

Purchase price information

The purchase price allocation was as follows:

			Noveprim Group(1)						SAMDI Tech, Inc.
			November 30, 2023						January 27, 2023
			(in thousands)
Trade receivables			$	1,308					$	513
Inventories			66,500						—
Other current assets (excluding cash)			3,261						75
Property, plant and equipment			36,154						593
Operating lease right-of-use asset, net			104						—
Goodwill (2)			190,024						37,129
Definite-lived intangible assets			9,500						33,070
Other long-term assets (3)			167,907						6
Deferred revenue			—						(43)
Other current liabilities			(16,268)						(351)
Operating lease right-of-use liabilities (Long-term)			(97)						—
Deferred tax liabilities			(12,984)						(8,191)
Other long-term liabilities			(7,579)						—
Redeemable noncontrolling interest (4)			(45,426)						—
Total purchase price allocation			$	392,404					$	62,801
(1) Purchase price allocation is preliminary and subject to change as additional information becomes available concerning the fair value and tax basis of the assets acquired and liabilities assumed, including certain contracts, obligations, and finalization of any working capital adjustments. Any additional adjustments to the purchase price allocation will be made as soon as practicable but no later than one year from the date of acquisition.
(2) The goodwill resulting from these transactions is primarily attributable to the potential growth of the Company’s segments from new customers introduced to the acquired businesses or synergies to be realized from acquiring an internal supplier servicing the DSA business and the assembled workforce of the acquirees, thus is not deductible for tax purposes.
(3) Other long-term assets acquired from the Noveprim acquisition include $167.8 million of biological assets, which will be amortized over an estimated eight-year useful life.
(4) Refer to Note 12. Equity and Noncontrolling Interests for further a description of the 10% noncontrolling interest fair value.

The definite-lived intangible assets acquired were as follows:

			Noveprim Group			SAMDI Tech, Inc.
Definite-Lived Intangible Assets			(in thousands)
Client relationships			$	—		$	23,400
Other intangible assets			9,500			9,670
Total definite-lived intangible assets			$	9,500		$	33,070
Weighted Average Amortization Life			(in years)
Client relationships			—			15
Other intangible assets			7			7
Total definite-lived intangible assets			7			12

---

Disaggregation of Revenue

The following table disaggregates the Company’s revenue by major business line and timing of transfer of products or services:

			Three Months Ended												Six Months Ended
			June 29, 2024						July 1, 2023						June 29, 2024						July 1, 2023
			(in thousands)
Timing of Revenue Recognition:
RMS
Services and products transferred over time			$	95,299					$	94,458					$	192,348					$	188,097
Services and products transferred at a point in time			111,090						115,490						234,948						221,617
Total RMS revenue			206,389						209,948						427,296						409,714
DSA
Services and products transferred over time			626,785						662,653						1,230,910						1,324,489
Services and products transferred at a point in time			634						804						1,961						1,321
Total DSA revenue			627,419						663,457						1,232,871						1,325,810
Manufacturing
Services and products transferred over time			104,481						100,460						204,539						186,546
Services and products transferred at a point in time			87,828						86,072						172,971						167,240
Total Manufacturing revenue			192,309						186,532						377,510						353,786
Total revenue			$	1,026,117					$	1,059,937					$	2,037,677					$	2,089,310

Contract Balances from Contracts with Customers

The following table provides information about client receivables, contract assets, and contract liabilities from contracts with customers:

			June 29, 2024						December 30, 2023
			(in thousands)
Assets from contracts with customers
Client receivables			$	568,283					$	578,077
Unbilled revenue			218,889						228,020
Total			787,172						806,097
Less: Allowance for credit losses			(24,951)						(25,722)
Trade receivables and contract assets, net			$	762,221					$	780,375
Liabilities from contracts with customers
Current deferred revenue			$	247,177					$	241,820
Long-term deferred revenue (included in Other long-term liabilities)			29,139						30,919
Customer contract deposits (included in Other current liabilities)			92,032						85,554

Approximately 85% of unbilled revenue as of December 30, 2023, which was $228 million, was billed during the six months ended June 29, 2024. Approximately 85% of unbilled revenue as of December 31, 2022, which was $204 million, was billed during the six months ended July 1, 2023.

Approximately 70% of contract liabilities as of December 30, 2023, which was $273 million, were recognized as revenue during the six months ended June 29, 2024. Approximately 75% of contract liabilities as of December 31, 2022, which was $290 million, were recognized as revenue during the six months ended July 1, 2023.

When the Company does not have the unconditional right to advanced billings, both advanced client payments and unpaid advanced client billings are excluded from deferred revenue, with the advanced billings also being excluded from client

---

receivables. The Company excluded approximately $46 million and $41 million of unpaid advanced client billings from both client receivables and deferred revenue in the accompanying unaudited condensed consolidated balance sheets as of June 29, 2024 and December 30, 2023, respectively.

Allowance for Credit Losses

The following is a summary of the activity of the Company’s allowance for credit losses:

									Six Months Ended
															June 29, 2024						July 1, 2023
															(in thousands)
Beginning balance															$	25,722					$	11,278
Provisions															4,719						9,849
Reductions															(5,490)						(3,087)
Ending balance															$	24,951					$	18,040

Net provision expenses were $4.1 million and $9.2 million during the six months ended June 29, 2024 and July 1, 2023, respectively and include recoveries of balances previously written off, which are excluded from the table above.

Transaction Price Allocated to Future Performance Obligations

The Company discloses the aggregate amount of transaction price that is allocated to performance obligations that have not yet been satisfied as of June 29, 2024. Excluded from the disclosure is the value of unsatisfied performance obligations for contracts with an original expected length of one year or less, contracts for which revenue is recognized at the amount to which the Company has the right to invoice for services performed, and service revenue recognized in accordance with ASC 842, “Leases”. The aggregate amount of transaction price allocated to the remaining performance obligations for all open customer contracts as of June 29, 2024 was $856.6 million. The Company will recognize revenues for these performance obligations as they are satisfied, approximately 50% of which is expected to occur within the next twelve months and the remainder recognized thereafter during the remaining contract term.

Other Performance Obligations

As part of the Company’s service offerings, the Company has identified performance obligations related to leasing Company owned assets. In certain arrangements, customers obtain substantially all of the economic benefits of the identified assets, which may include manufacturing suites and related equipment, and have the right to direct the assets’ use over the term of the contract. The associated revenue is recognized on a straight-line basis over the term of the lease, which is generally less than one year.

			Three Months Ended												Six Months Ended
			June 29, 2024						July 1, 2023						June 29, 2024						July 1, 2023
			(in thousands)																								Affected Line Item in the Unaudited Condensed Consolidated Statements of Income
Lease revenue			$	16,716					$	23,891					$	37,690					$	47,981					Service revenue

---

The Company operates in three reportable segments, RMS, DSA and Manufacturing. Asset information on a reportable segment basis is not disclosed as this information is not separately identified and internally reported to the Company’s Chief Operating Decision Maker (CODM). The following table presents the results of operations by reportable segment:

			Three Months Ended												Six Months Ended
			June 29, 2024						July 1, 2023						June 29, 2024						July 1, 2023
			(in thousands)
RMS
Revenue			$	206,389					$	209,948					$	427,296					$	409,714
Cost of revenue (excluding amortization of intangible assets)			142,942						127,888						283,867						254,692
Selling, general and administrative			27,597						27,653						58,490						54,711
Amortization of intangible assets			5,902						5,489						11,842						10,984
Operating income			$	29,948					$	48,918					$	73,097					$	89,327
DSA
Revenue			$	627,419					$	663,457					$	1,232,871					$	1,325,810
Cost of revenue (excluding amortization of intangible assets)			418,964						420,551						836,876						832,074
Selling, general and administrative			54,479						63,709						111,338						125,707
Amortization of intangible assets			15,600						17,659						31,442						35,060
Operating income			$	138,376					$	161,538					$	253,215					$	332,969
Manufacturing
Revenue			$	192,309					$	186,532					$	377,510					$	353,786
Cost of revenue (excluding amortization of intangible assets)			110,498						112,522						218,378						225,914
Selling, general and administrative			33,813						38,481						66,660						78,218
Amortization of intangible assets			10,768						11,126						21,561						23,145
Operating income			$	37,230					$	24,403					$	70,911					$	26,509
Unallocated Corporate
Selling, general and administrative			$	53,902					$	69,914					$	119,594					$	115,968
Operating income (1)			$	(53,902)					$	(69,914)					$	(119,594)					$	(115,968)
Consolidated
Revenue			$	1,026,117					$	1,059,937					$	2,037,677					$	2,089,310
Cost of revenue (excluding amortization of intangible assets)			672,404						660,960						1,339,121						1,312,679
Selling, general and administrative			169,791						199,758						356,082						374,604
Amortization of intangible assets			32,270						34,274						64,845						69,190
Operating income			$	151,652					$	164,945					$	277,629					$	332,837
(1) Operating income for unallocated corporate consists of costs associated with departments such as senior executives, corporate accounting, legal, tax, human resources, treasury, and investor relations.

---

Capital expenditures and depreciation and amortization (related to both intangible assets and certain assets acquired in business combinations) by reportable segment are as follows:

			RMS						DSA						Manufacturing						Unallocated Corporate						Consolidated
			(in thousands)
Capital Expenditures
Three Months Ended:
June 29, 2024			$	9,313					$	19,444					$	10,583					$	146					$	39,486
July 1, 2023			7,493						48,326						10,862						702						67,383
Six Months Ended:
June 29, 2024			$	29,357					$	68,403					$	19,445					$	1,425					$	118,630
July 1, 2023			26,577						113,510						32,600						1,571						174,258
Depreciation and amortization
Three Months Ended:
June 29, 2024			$	16,538					$	47,729					$	20,073					$	1,742					$	86,082
July 1, 2023			13,949						43,124						19,523						1,075						77,671
Six Months Ended:
June 29, 2024			$	34,661					$	93,518					$	39,878					$	3,382					$	171,439
July 1, 2023			27,438						85,574						39,607						2,121						154,740

Revenue by geographic area is as follows:

			U.S.						Europe						Canada						Asia Pacific						Other						Consolidated
			(in thousands)
Three Months Ended:
June 29, 2024			$	571,427					$	271,377					$	125,244					$	50,387					$	7,682					$	1,026,117
July 1, 2023			606,775						272,976						117,647						59,864						2,675						1,059,937
Six Months Ended:
June 29, 2024			$	1,133,744					$	547,696					$	235,645					$	96,159					$	24,433					$	2,037,677
July 1, 2023			1,212,216						540,679						228,253						102,677						5,485						2,089,310

Included in the Other category above are operations located in Brazil, Israel, and Mauritius. Revenue represents sales originating in entities physically located in the identified geographic area.

Long-lived assets by geographic area are as follows:

			U.S.						Europe						Canada						Asia Pacific						Other						Consolidated
			(in thousands)
Long-lived assets
June 29, 2024			$	950,254					$	405,429					$	153,945					$	68,868					$	35,399					$	1,613,895
December 30, 2023			964,176						407,375						157,483						74,605						36,102						1,639,741

Long-lived assets consist of property, plant, and equipment, net.

---

			Six Months Ended
			June 29, 2024						July 1, 2023
			(in thousands)
Cash paid for income taxes			$	71,722					$	61,816
Cash paid for interest			65,630						66,563
Non-cash investing activities:
Purchases of Property, plant and equipment included in Accounts payable and Accrued liabilities			$	25,278					$	47,850
Assets acquired under finance leases			3,159						154

Cash, cash equivalents and restricted cash is included in the accompanying unaudited balance sheet as follows:

			June 29, 2024						December 30, 2023
			(in thousands)
Supplemental cash flow information:
Cash and cash equivalents			$	179,213					$	276,771
Restricted cash included in Other current assets			325						5,803
Restricted cash included in Other assets			1,466						1,906
Cash, cash equivalents, and restricted cash, end of period			$	181,004					$	284,480

Inventories

The composition of inventories is as follows:

			June 29, 2024						December 30, 2023
			(in thousands)
Raw materials and supplies			$	43,238					$	42,296
Work in process			57,923						59,727
Finished products			247,950						278,236
Inventories			$	349,111					$	380,259

The composition of property, plant and equipment, net is as follows:

			June 29, 2024						December 30, 2023
			(in thousands)
Land			$	78,812					$	79,546
Buildings (1)			1,061,408						1,053,915
Machinery and equipment (1)			1,007,210						984,867
Leasehold improvements			381,879						366,556
Furniture and fixtures			32,060						31,284
Computer hardware and software (1)			259,889						254,413
Vehicles (1)			7,149						6,746
Construction in progress			182,823						197,723
Total			3,011,230						2,975,050
Less: Accumulated depreciation			(1,397,335)						(1,335,309)
Property, plant and equipment, net			$	1,613,895					$	1,639,741
(1) These balances include assets under finance leases.

---

Venture capital investments are summarized below:

			Six Months Ended
			June 29, 2024						July 1, 2023
			(in thousands)
Beginning balance			$	121,158					$	129,012
Capital contributions			6,479						8,702
Distributions			(16,100)						(9,679)
Gains (losses)			1,789						(8,429)
Foreign currency translation			(249)						466
Ending balance			$	113,077					$	120,072

The Company also invests, with minority positions, directly in equity of predominantly privately held companies. Strategic investments are summarized below:

			Six Months Ended
			June 29, 2024						July 1, 2023
			(in thousands)
Beginning balance			$	122,653					$	182,590
Purchase of investments			2,140						13,710
Distributions			—						(4,146)
Gain (loss)			(5,265)						3,253
Reduction for acquisition of entity (1)			—						(12,635)
Foreign currency translation			(746)						(2,563)
Ending balance			$	118,782					$	180,209
(1) Refer to Note 2. Acquisitions for further discussion on the acquisition of SAMDI.

Assets and liabilities measured at fair value on a recurring basis are summarized below:

			June 29, 2024
			Level 1						Level 2						Level 3						Total
Current assets measured at fair value:			(in thousands)
Cash equivalents			$	—					$	7,257					$	—					$	7,257
Term deposit			—						26,983						—						26,983
Other assets:
Life insurance policies			—						45,210						—						45,210
Interest rate swap			—						1,338						—						1,338
Total assets measured at fair value			$	—					$	80,788					$	—					$	80,788
Other long-term liabilities measured at fair value:
Contingent consideration			$	—					$	—					$	38,335					$	38,335
Total liabilities measured at fair value			$	—					$	—					$	38,335					$	38,335

The Company recognizes transfers between levels within the fair value hierarchy, if any, at the end of each quarter. During the six months ended June 29, 2024, there were no transfers between levels.

---

			December 30, 2023
			Level 1						Level 2						Level 3						Total
Current assets measured at fair value:			(in thousands)
Cash equivalents			$	—					$	29					$	—					$	29
Other assets:
Life insurance policies			—						40,912						—						40,912
Interest rate swap			—						966						—						966
Total assets measured at fair value			$	—					$	41,907					$	—					$	41,907
Other long-term liabilities measured at fair value
Contingent consideration			$	—					$	—					$	33,265					$	33,265
Total liabilities measured at fair value			$	—					$	—					$	33,265					$	33,265

During the year ended December 30, 2023, there were no transfers between levels.

Contingent Consideration

The following table provides a rollforward of the contingent consideration related to the Company’s acquisitions.

			Six Months Ended
			June 29, 2024						July 1, 2023
			(in thousands)
Beginning balance			$	33,265					$	13,431
Payments			—						(15,130)
Total gains or losses (realized/unrealized):
Adjustment of previously recorded contingent liability			5,070						1,810
Foreign currency translation			—						(111)
Ending balance			$	38,335					$	—

The Company estimates the fair value of contingent consideration obligations through valuation models, such as probability-weighted and option pricing models, which incorporate probability adjusted assumptions and simulations related to the achievement of the milestones and the likelihood of making related payments. The unobservable inputs used in the fair value measurements include the probabilities of successful achievement of certain financial targets, forecasted results or targets, volatility, and discount rates. The remaining maximum potential payments are approximately $55 million, of which the value accrued as of June 29, 2024 is $38 million as the probability of achieving the maximum target is estimated to be 70%. The volatility and weighted average cost of capital is approximately 5% and 8%, respectively. Increases or decreases in these assumptions may result in a higher or lower fair value measurement, respectively.

Cash Flow Hedge

The Company is exposed to market fluctuations in interest rates as well as variability in foreign exchange rates. The Company has an interest rate swap with a notional amount of $500 million maturing November 2, 2024 to manage interest rate fluctuation related to floating rate borrowings under the Credit Facility, at a fixed rate of 4.65%.

Debt Instruments

The book value of the Company’s revolving loans, which are variable rate loans carried at amortized cost, approximates the fair value based on current market pricing of similar debt. As the fair value is based on significant other observable inputs, including current interest and foreign currency exchange rates, it is deemed to be Level 2 within the fair value hierarchy.

The book value of the Company’s Senior Notes are fixed rate obligations carried at amortized cost. Fair value is based on quoted market prices as well as borrowing rates available to the Company. As the fair value is based on significant other

---

observable outputs, it is deemed to be Level 2 within the fair value hierarchy. The book value and fair value of the Company’s Senior Notes is summarized below:

			June 29, 2024												December 30, 2023
			Book Value						Fair Value						Book Value						Fair Value
			(in thousands)
4.25% Senior Notes due 2028			$	500,000					$	468,750					$	500,000					$	478,100
3.75% Senior Notes due 2029			500,000						453,750						500,000						458,100
4.00% Senior Notes due 2031			500,000						445,000						500,000						449,350

Goodwill

The following table provides a rollforward of the Company’s goodwill:

			RMS						DSA (1)						Manufacturing						Total
			(in thousands)
December 30, 2023			$	497,474					$	1,662,434					$	935,137					$	3,095,045
Acquisitions			—						17,675						—						17,675
Foreign exchange			(536)						(29,251)						(3,240)						(33,027)
June 29, 2024			$	496,938					$	1,650,858					$	931,897					$	3,079,693
(1) DSA includes accumulated impairment losses of $1 billion, which were recognized in fiscal years 2008 and 2010.

The decrease in goodwill during the six months ended June 29, 2024 is related to foreign exchange in the DSA and Manufacturing reportable segments, partially offset by measurement period adjustments related to the acquisition of Noveprim in the DSA reportable segment.

Intangible Assets, Net

The following table displays intangible assets, net by major class:

			June 29, 2024																		December 30, 2023
			Gross						Accumulated Amortization						Net						Gross						Accumulated Amortization						Net
			(in thousands)
Client relationships			$	1,518,194					$	(766,261)					$	751,933					$	1,528,780					$	(721,322)					$	807,458
Technology			140,737						(114,410)						26,327						142,190						(111,764)						30,426
Trademarks and trade names			11,849						(5,098)						6,751						11,878						(4,568)						7,310
Backlog			3,100						(2,792)						308						3,100						(2,177)						923
Other			42,866						(28,056)						14,810						43,611						(25,677)						17,934
Intangible assets			$	1,716,746					$	(916,617)					$	800,129					$	1,729,559					$	(865,508)					$	864,051

The decrease in intangible assets, net during the six months ended June 29, 2024 related to normal amortization over the useful lives.

---

Long-term debt, net and finance leases consists of the following:

			June 29, 2024						December 30, 2023
			(in thousands)
Revolving facility			$	879,498					$	1,129,243
4.25% Senior Notes due 2028			500,000						500,000
3.75% Senior Notes due 2029			500,000						500,000
4.00% Senior Notes due 2031			500,000						500,000
Other debt			16,125						9,575
Finance leases			29,637						28,550
Total debt and finance leases			2,425,260						2,667,368
Less:
Current portion of long-term debt			435						3,172
Current portion of finance leases			2,778						2,398
Current portion of long-term debt and finance leases			3,213						5,570
Long-term debt and finance leases			2,422,047						2,661,798
Debt discount and debt issuance costs			(12,667)						(14,651)
Long-term debt, net and finance leases			$	2,409,380					$	2,647,147

As of June 29, 2024 and December 30, 2023, the weighted average interest rate on the Company’s debt was 4.64% and 4.93%, respectively.

Letters of Credit

---

Earnings Per Share

The following table reconciles the numerator and denominator in the computations of basic and diluted earnings per share:

			Three Months Ended												Six Months Ended
			June 29, 2024						July 1, 2023						June 29, 2024						July 1, 2023
			(in thousands)
Numerator:
Net income			$	94,261					$	99,443					$	168,743					$	203,397
Less: Net income attributable to noncontrolling interests			180						2,423						1,702						3,246
Net income available to Charles River Laboratories International, Inc.			94,081						97,020						167,041						200,151
Calculation of net income per share attributable to common shareholders of Charles River Laboratories International, Inc.
Net income available to Charles River Laboratories International, Inc.			$	94,081					$	97,020					$	167,041					$	200,151
Less: Adjustment of redeemable noncontrolling interest (1)			301						—						702						—
Less: Incremental dividends attributable to noncontrolling interest holders (2)			3,792						—						9,022						—
Net income available to Charles River Laboratories International, Inc. common shareholders			$	89,988					$	97,020					$	157,317					$	200,151
Denominator:
Weighted-average shares outstanding - Basic			51,551						51,216						51,494						51,157
Effect of dilutive securities:
Stock options, restricted stock units and performance share units			295						251						316						225
Weighted-average shares outstanding - Diluted			51,846						51,467						51,810						51,382
Anti-dilutive common stock equivalents (3)			506						594						482						589
(1) Represents adjustments of redeemable noncontrolling interest that impact retained earnings.
(2) Represents incremental undeclared dividends attributable to Noveprim noncontrolling interest holders who are entitled to preferential dividends for fiscal year 2024.
(3) These common stock equivalents were outstanding for the periods presented, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.

Treasury Shares

The Company’s Board of Directors had authorized a $1.3 billion stock repurchase program. As of June 29, 2024, the Company had $129.1 million remaining on the authorized stock repurchase program.

On August 2, 2024, the Company’s Board of Directors approved a new stock repurchase authorization of $1.0 billion. This new authorization replaces the prior stock repurchase authorization of $1.3 billion that had $129.1 million remaining on the plan when it was terminated.

The Company’s stock-based compensation plans permit the netting of common stock upon vesting of RSUs and PSUs in order to satisfy individual statutory tax withholding requirements. The Company acquired shares of approximately 0.1 million in the six months ended June 29, 2024 and six months ended July 1, 2023, for $18.3 million and $24.0 million, respectively, from such netting.

---

Accumulated Other Comprehensive Income (Loss)

Changes to each component of accumulated other comprehensive income (loss), net of income taxes, are as follows:

			Foreign Currency Translation Adjustment and Other						Pension and Other Post-Retirement Benefit Plans						Net Unrealized (Loss) Gain on Cash Flow Hedge						Total
			(in thousands)
December 30, 2023			$	(149,999)					$	(47,167)					$	739					$	(196,427)
Other comprehensive income (loss) before reclassifications			(81,840)						686						372						(80,782)
Net current period other comprehensive income (loss)			(81,840)						686						372						(80,782)
Income tax expense (benefit)			(7,759)						170						89						(7,500)
June 29, 2024			$	(224,080)					$	(46,651)					$	1,022					$	(269,709)

Redeemable Noncontrolling Interests

Through June 29, 2024, the Company holds several redeemable noncontrolling interests. Since the Company has the right to purchase, and the noncontrolling interest holders have the right to require the Company to purchase the remaining interest, which represents a derivative embedded within the equity instrument, the noncontrolling interest is classified in the mezzanine section of the unaudited condensed consolidated balance sheets, which is presented above the equity section and below liabilities.

The redeemable noncontrolling interests are measured at the greater of (i) the redemption amount or (ii) the historical value resulting from the original acquisition date fair value, increased or decreased for the noncontrolling interest’s share of net income (loss), equity capital contributions and distributions. The fair value of the redeemable noncontrolling interest is determined using the income approach, with key assumptions being projected cash flows and discount rates based on market participant’s weighted average cost of capital. To the extent redemption value exceeds carrying value, adjustments are recorded to additional paid-in capital, with any cumulative excess of redemption value over fair value recorded in retained earnings, which impacts net income available to common shareholders used in the calculation of earnings per common share.

Noveprim

The Company holds a 90% ownership interest in Noveprim. The Company has the right to purchase, and the noncontrolling interest holders have the right to sell, the remaining 10% equity interest at a fixed redemption value that ranges from $47.0 million to $54.0 million depending on when exercised. The Company has the call option right to purchase the remaining 10% equity up until one month after the sixth anniversary of closing the 41% equity stake (December 2029). On the first anniversary of the expiration of the call option (December 2030), a 12-month put option will be triggered giving the seller the right to require the Company to acquire the remaining shares of the seller for $54.0 million. Additionally, during fiscal year 2024 the 10% noncontrolling interest holders may receive a dividend disproportionate to their equity ownership, of which the fair value of $8.0 million as of the acquisition date was recorded within the redeemable noncontrolling interest. Through June 29, 2024, incremental dividends based on Noveprim statutory net income attributed to the redeemable noncontrolling interest holders of $9.0 million reduced net income available to common shareholders used in the calculation of earnings per common share. The redemption value is accreted to the put purchase price of $54.0 million using the interest method through December 2030. As of June 29, 2024, the redemption value of $46.1 million exceeded both the carrying value and fair value, resulting in both an adjustment to additional paid in capital of $1.8 million and an adjustment to retained earnings of $0.7 million, respectively.

Other redeemable noncontrolling interest

In 2019, the Company acquired an 80% equity interest in a subsidiary, which included a 20% redeemable noncontrolling interest. In June 2022, the Company purchased an additional 10% interest in the subsidiary for $15.0 million, resulting in a remaining noncontrolling interest of 10%. Beginning in 2024, the Company has the right to purchase, and the noncontrolling interest holders have the right to sell, the remaining 10% equity interest at its appraised value. The redemption value is measured at the greater of the appraised value or a predetermined floor. The amount that the Company could be required to pay to purchase the remaining 10% equity interest is not limited. As of March 30, 2024, the redemption value of $12.0 million exceeded the carrying value, resulting in an adjustment to additional paid in capital of $2.8 million. During the second quarter of fiscal 2024, the Company acquired the remaining 10% for $12.0 million.

---

Vital River

The Company held a 92% ownership interest in Vital River, a commercial provider of research models and related services in China as of December 31, 2022. The Company had the right to purchase, and the noncontrolling interest holders had the right to sell, the remaining 8% equity interest at a contractually defined redemption value, subject to a redemption floor. The amount that the Company could be required to pay to purchase the remaining 8% equity interest was not limited. During the fourth quarter of fiscal 2023, the Company acquired the remaining 8% and paid $4.8 million of the total $24.4 million due. The remaining purchase price payable was included in Accrued liabilities within the Company’s unaudited condensed consolidated balance sheet as of June 29, 2024 and December 30, 2023 and is expected to be paid during fiscal year 2024.

Nonredeemable Noncontrolling Interest

The Company’s effective tax rates for the three months ended June 29, 2024 and July 1, 2023 were 21.2% and 22.7%, respectively. The decrease in the effective tax rate for the three months ended June 29, 2024 compared to the corresponding prior year period was primarily attributable to non-taxable remeasurement gains on previous equity investment in Noveprim during the three months ended June 29, 2024.

The Company’s effective tax rates for the six months ended June 29, 2024 and July 1, 2023 were 22.8% and 21.7%, respectively. The increase in the effective tax rate for the six months ended June 29, 2024 compared to the same prior year is primarily attributable to decreased tax benefit from stock-based compensation deductions in the six months ended June 29, 2024.

For the three months ended June 29, 2024, the Company’s unrecognized tax benefits increased by $0.6 million to $24.0 million, primarily due to increases in research and development tax credit reserves. For the three months ended June 29, 2024, the amount of unrecognized income tax benefits that would impact the effective tax rate increased by $0.4 million to $21.1 million for the same reasons discussed above. The accrued interest on unrecognized tax benefits was $1.6 million as of June 29, 2024. The Company estimates that it is reasonably possible that the unrecognized tax benefits will decrease by approximately $5 million over the next twelve-month period, primarily due to audit settlements and expiring statutes of limitations.

The Company’s prepaid and accrued tax positions are as follows:

			June 29, 2024						December 30, 2023			Affected Line Item in the Unaudited Condensed Consolidated Balance Sheets
			(in thousands)
Prepaid income tax			$	71,242					$	59,715		Other current assets
Accrued income taxes			35,126						38,819			Other current liabilities

The Company conducts business in a number of tax jurisdictions. As a result, it is subject to tax audits on a regular basis including, but not limited to, such major jurisdictions as the U.S., the U.K., China, France, Germany, and Canada. With few exceptions, the Company is no longer subject to U.S. and international income tax examinations for years before 2020.

The Company and certain of its subsidiaries have ongoing tax controversies in the U.S., Canada, and India. The Company does not anticipate resolution of these audits will have a material impact on its unaudited condensed consolidated financial statements.

The Company has undertaken restructuring actions impacting the reportable segments at various locations across North America, Europe and Asia. This includes workforce right-sizing actions resulting in severance and transition costs; and costs related to the consolidation of facilities resulting in asset impairment and accelerated depreciation charges. Generally, these actions are considered to be short-term in nature in response to recent macroeconomic impacts on the Company. During fiscal year 2023, the Company began to take restructuring actions as a result of these emerging business trends. The Company incurred restructuring charges of $18.0 million and $35.0 million during the three and six months ended June 29, 2024, respectively and approximately $65 million throughout fiscal year 2023 through June 29, 2024.

---

The following table presents restructuring costs by reportable segment:

			Three Months Ended												Six Months Ended
			June 29, 2024						July 1, 2023						June 29, 2024						July 1, 2023
			(in thousands)
RMS			$	10,228					$	—					$	17,615					$	—
DSA			3,766						—						10,257						(2)
Manufacturing			2,657						2,699						4,288						6,187
Unallocated corporate			1,304						—						2,794						—
Total			$	17,955					$	2,699					$	34,954					$	6,185

The following table presents restructuring costs as included within the Company’s unaudited condensed consolidated statements of income:

			June 29, 2024																		July 1, 2023
			Severance and Transition Costs						Asset Impairments and Other Costs						Total						Severance and Transition Costs						Asset Impairments and Other Costs						Total
			(in thousands)
Three Months Ended
Cost of services provided (excluding amortization of intangible assets)			$	2,870					$	1,926					$	4,796					$	2,361					$	—					$	2,361
Cost of products sold (excluding amortization of intangible assets)			69						9,154						9,223						36						182						218
Selling, general and administrative			2,958						978						3,936						120						—						120
Total restructuring costs			$	5,897					$	12,058					$	17,955					$	2,517					$	182					$	2,699
Six Months Ended
Cost of services provided (excluding amortization of intangible assets)			$	7,680					$	3,034					$	10,714					$	2,928					$	—					$	2,928
Cost of products sold (excluding amortization of intangible assets)			747						10,484						11,231						54						2,746						2,800
Selling, general and administrative			6,507						6,502						13,009						449						8						457
Total restructuring costs			$	14,934					$	20,020					$	34,954					$	3,431					$	2,754					$	6,185

---

Rollforward of Restructuring Activities

The following table provides a rollforward for the Company’s accrued restructuring costs related to all restructuring activities:

			Severance and Transition Costs						Asset Impairments						Other Costs						Total
			(in thousands)
Six Months Ended June 29, 2024
Beginning balance			$	4,175					$	—					$	875					$	5,050
Expense			14,934						14,181						5,839						34,954
Payments / utilization			(9,323)						—						(5,067)						(14,390)
Other non-cash adjustments			—						(14,181)						(772)						(14,953)
Foreign currency adjustments			(57)						—						—						(57)
Ending Balance			$	9,729					$	—					$	875					$	10,604
Six Months Ended July 1, 2023
Beginning balance			$	356					$	—					$	944					$	1,300
Expense			3,431						2,479						275						6,185
Payments / utilization			(811)						—						(303)						(1,114)
Other non-cash adjustments			—						(2,479)						—						(2,479)
Foreign currency adjustments			9						—						—						9
Ending Balance			$	2,985					$	—					$	916					$	3,901

Litigation

On February 16, 2023, the Company was informed by the U.S. Department of Justice (DOJ) that in conjunction with the U.S. Fish and Wildlife Service (USFWS), it had commenced an investigation into the Company’s conduct regarding several shipments of non-human primates from Cambodia. On February 17, 2023 the Company received a grand jury subpoena requesting certain documents related to such investigation. The Company is aware of a parallel civil investigation being undertaken by the DOJ and USFWS. The Company is cooperating with the DOJ and the USFWS and believes that the concerns raised with respect to the Company’s conduct are without merit. The Company maintains a global supplier onboarding and oversight program incorporating risk-based due diligence, auditing, and monitoring practices to help ensure the quality of our supplier relationships and compliance with applicable U.S. and international laws and regulations, and has operated under the belief that all shipments of non-human primates it received satisfied the material requirements, documentation and related processes and procedures of the Convention on International Trade in Endangered Species of Wild Fauna and Flora (CITES) documentation and related processes and procedures, which guides the release of each import by USFWS. Notwithstanding our efforts and good-faith belief, in connection with the civil investigation, the Company has voluntarily suspended future shipments of non-human primates from Cambodia to the United States until such time that the Company and USFWS can agree upon and implement additional procedures to reasonably ensure that non-human primates imported from Cambodia are purpose-bred. The Company continues to care for the Cambodia-sourced non-human primates from certain shipments in the United States. The carrying value of the inventory related to these shipments was approximately $27 million as of June 29, 2024, which reflects the value of the shipments in accordance with the Company’s inventory accounting policy. On May 16, 2023, the Company received an inquiry from the Enforcement Division of the U.S. Securities and Exchange Commission (SEC) requesting it to voluntarily provide information, subsequently augmented with a document subpoena and additional inquiries, primarily related to the sourcing of non-human primates and related disclosures, and the Company is cooperating with these requests. The Company is not able to predict what action, if any, might be taken in the future by the DOJ, USFWS, SEC or other governmental authorities as a result of the investigations. None of the DOJ, USFWS or SEC has provided the Company with any specific timeline or indication as to when these investigations or, specific to the DOJ and USFWS, discussions regarding future processes and procedures, will be concluded or resolved. The Company cannot predict the timing, outcome or possible impact of the investigations, including without limitation any potential fines, penalties or liabilities.

A putative securities class action (Securities Class Action) was filed on May 19, 2023 against the Company and a number of its current/former officers in the United States District Court for the District of Massachusetts. On August 31, 2023, the court appointed the State Teachers Retirement System of Ohio as lead plaintiff. An amended complaint was filed on November 14, 2023 that, among other things, included only James Foster, the Chief Executive Officer and David R. Smith, the former Chief

---

Financial Officer as defendants along with the Company. The amended complaint asserts claims under §§ 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") on behalf of a putative class of purchasers of Company securities from May 5, 2020 through February 21, 2023, alleging that certain of the Company’s disclosures about its practices with respect to the importation of non-human primates made during the putative class period were materially false or misleading. On July 1, 2024, the court dismissed the complaint, denied the plaintiff’s informal request for leave to amend, and entered judgment for defendants. On July 30, 2024 the plaintiff filed a notice of appeal. While the Company cannot predict the final outcome of this matter, it believes the class action to be without merit and plans to vigorously defend against it. The Company cannot reasonably estimate the maximum potential exposure or the range of possible loss in association with this matter.

On November 8, 2023, a stockholder filed a derivative lawsuit in the U.S. District Court of the District of Delaware asserting claims on the Company’s behalf against the members of the Company’s Board of Directors and certain of the Company’s current/former officers (James Foster, the Chief Executive Officer; David R. Smith, the former Chief Financial Officer; and Flavia Pease, the current Chief Financial Officer). The complaint alleges that the defendants breached their fiduciary duties to the Company and its stockholders because certain of the Company’s disclosures about its practices with respect to the importation of non-human primates were materially false or misleading. The complaint also alleges that the defendants breached their fiduciary duties by causing the Company to fail to maintain adequate internal controls over securities disclosure and compliance with applicable law and by failing to comply with the company’s Code of Business Conduct and Ethics. The lawsuit is currently stayed by agreement of the parties pending further developments in the Securities Class Action pending in the United States District Court for the District of Massachusetts. On August 2, 2024, a different stockholder filed a lawsuit in the U.S. District Court of Delaware asserting similar derivative claims on the Company’s behalf against members of the Company’s current and former Board of Directors and the same current/former officers based on similar allegations of purportedly misleading disclosures and non-compliance with legal rules and ethics standards in respect of the importation of non-human primates, as well as insider-trading claims against certain of the defendants. While the Company cannot predict the outcome of these matters, it believes the derivative lawsuits to be without merit and plans to vigorously defend against them. The Company cannot reasonably estimate the maximum potential exposure or the range of possible loss in association with these matters.

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

v3.24.2.u1

Cover Page - shares	6 Months Ended
	Jun. 29, 2024	Jul. 27, 2024
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 29, 2024
Document Transition Report	false
Entity File Number	001-15943
Entity Registrant Name	CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	06-1397316
Entity Address, Address Line One	251 Ballardvale Street
Entity Address, City or Town	Wilmington
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	01887
City Area Code	781
Local Phone Number	222-6000
Title of 12(b) Security	Common stock, $0.01 par value
Trading Symbol	CRL
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Smaller Reporting Company	false
Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		51,630,726
Entity Central Index Key	0001100682
Current Fiscal Year End Date	--12-28
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q2
Amendment Flag	false

v3.24.2.u1

CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 29, 2024	Jul. 01, 2023	Jun. 29, 2024	Jul. 01, 2023
Total revenue	$ 1,026,117	$ 1,059,937	$ 2,037,677	$ 2,089,310
Costs and expenses:
Cost of revenue (excluding amortization of intangible assets)	672,404	660,960	1,339,121	1,312,679
Selling, general and administrative	169,791	199,758	356,082	374,604
Amortization of intangible assets	32,270	34,274	64,845	69,190
Operating income	151,652	164,945	277,629	332,837
Other income (expense):
Interest income	3,010	1,426	5,212	2,232
Interest expense	(32,769)	(35,044)	(67,770)	(69,424)
Other income (expense), net	(2,240)	(2,663)	3,593	(5,940)
Income before income taxes	119,653	128,664	218,664	259,705
Provision for income taxes	25,392	29,221	49,921	56,308
Net income	94,261	99,443	168,743	203,397
Less: Net income attributable to noncontrolling interests	180	2,423	1,702	3,246
Net income available to Charles River Laboratories International, Inc.	94,081	97,020	167,041	200,151
Calculation of net income per share attributable to common shareholders of Charles River Laboratories International, Inc.
Net income available to Charles River Laboratories International, Inc.	94,081	97,020	167,041	200,151
Less: Adjustment of redeemable noncontrolling interest	301	0	702	0
Less: Incremental dividends attributable to noncontrolling interest holders	3,792	0	9,022	0
Net income available to Charles River Laboratories International, Inc. common shareholders	$ 89,988	$ 97,020	$ 157,317	$ 200,151
Net income attributable to common shareholders:
Basic (in dollars per share)	$ 1.75	$ 1.89	$ 3.06	$ 3.91
Diluted (in dollars per share)	$ 1.74	$ 1.89	$ 3.04	$ 3.90
Weighted-average number of common shares outstanding:
Basic (in shares)	51,551	51,216	51,494	51,157
Diluted (in shares)	51,846	51,467	51,810	51,382
Service
Total revenue	$ 842,900	$ 874,891	$ 1,659,762	$ 1,732,257
Costs and expenses:
Cost of revenue (excluding amortization of intangible assets)	577,383	578,099	1,155,547	1,143,576
Product
Total revenue	183,217	185,046	377,915	357,053
Costs and expenses:
Cost of revenue (excluding amortization of intangible assets)	$ 95,021	$ 82,861	$ 183,574	$ 169,103

v3.24.2.u1

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 29, 2024	Jul. 01, 2023	Jun. 29, 2024	Jul. 01, 2023
Statement of Comprehensive Income [Abstract]
Net income	$ 94,261	$ 99,443	$ 168,743	$ 203,397
Other comprehensive income (loss):
Foreign currency translation adjustment	(21,678)	23,227	(84,518)	46,540
Amortization of net loss, settlement losses, and prior service benefit included in total cost for pension and other post-retirement benefit plans	342	174	686	344
Unrealized gains (losses) on hedging instruments	(396)	6,046	372	4,644
Other comprehensive income (loss), before income taxes	(21,732)	29,447	(83,460)	51,528
Less: Income tax expense (benefit) related to items of other comprehensive income	(2,027)	937	(7,500)	(101)
Comprehensive income, net of income taxes	74,556	127,953	92,783	255,026
Less: Comprehensive income (loss) related to noncontrolling interests, net of income taxes	265	78	(976)	1,087
Comprehensive income attributable to Charles River Laboratories International, Inc., net of income taxes	$ 74,291	$ 127,875	$ 93,759	$ 253,939

v3.24.2.u1

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) - USD ($) $ in Thousands	Jun. 29, 2024	Dec. 30, 2023
Current assets:
Cash and cash equivalents	$ 179,213	$ 276,771
Trade receivables and contract assets, net of allowances for credit losses of $24,951 and $25,722, respectively	762,221	780,375
Inventories	349,111	380,259
Prepaid assets	97,892	87,879
Other current assets	110,836	83,378
Total current assets	1,499,273	1,608,662
Property, plant and equipment, net	1,613,895	1,639,741
Venture capital and strategic equity investments	231,859	243,811
Operating lease right-of-use assets, net	386,147	394,029
Goodwill	3,079,693	3,095,045
Intangible assets, net	800,129	864,051
Deferred tax assets	36,109	40,279
Other assets	301,178	309,383
Total assets	7,948,283	8,195,001
Current liabilities:
Accounts payable	133,101	168,937
Accrued compensation	176,667	213,290
Deferred revenue	247,177	241,820
Accrued liabilities	192,156	227,825
Other current liabilities	198,418	203,210
Total current liabilities	947,519	1,055,082
Long-term debt, net and finance leases	2,409,380	2,647,147
Operating lease right-of-use liabilities	428,587	419,234
Deferred tax liabilities	165,183	191,349
Other long-term liabilities	224,520	223,191
Total liabilities	4,175,189	4,536,003
Commitments and contingencies (Notes 2, 11, 13, and 15)
Redeemable noncontrolling interest	46,076	56,722
Equity:
Preferred stock, $0.01 par value; 20,000 shares authorized; no shares issued and outstanding	0	0
Common stock, $0.01 par value; 120,000 shares authorized; 51,696 shares issued and 51,613 shares outstanding as of June 29, 2024, and 51,338 shares issued and outstanding as of December 30, 2023	517	513
Additional paid-in capital	1,956,629	1,905,578
Retained earnings	2,053,557	1,887,218
Treasury stock, at cost, 83 and zero shares, as of June 29, 2024 and December 30, 2023, respectively	(18,265)	0
Accumulated other comprehensive loss	(269,709)	(196,427)
Total Charles River Laboratories International, Inc. equity	3,722,729	3,596,882
Nonredeemable noncontrolling interests	4,289	5,394
Total equity	3,727,018	3,602,276
Total liabilities, noncontrolling interests and equity	$ 7,948,283	$ 8,195,001

v3.24.2.u1

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) - USD ($) $ in Thousands	Jun. 29, 2024	Dec. 30, 2023
Statement of Financial Position [Abstract]
Less: Allowance for credit losses	$ 24,951	$ 25,722
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	20,000,000	20,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	120,000,000	120,000,000
Common stock, shares issued (in shares)	51,696,000	51,338,000
Common stock, shares outstanding (in shares)	51,613,000	51,338,000
Treasury stock, shares (in shares)	83,000	0

v3.24.2.u1

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($) $ in Thousands	6 Months Ended
	Jun. 29, 2024	Jul. 01, 2023
Cash flows relating to operating activities
Net income	$ 168,743	$ 203,397
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	171,439	154,740
Stock-based compensation	33,325	29,730
Deferred income taxes	(13,073)	(16,555)
Long-lived asset impairment charges	14,250	10,453
(Gain) loss on venture capital & strategic equity investments, net	(6,305)	5,176
Provision for credit losses	4,719	9,849
Loss on divestitures, net	659	563
Other, net	9,090	3,229
Changes in assets and liabilities:
Trade receivables and contract assets, net	1,072	(48,249)
Inventories	9,750	(32,671)
Accounts payable	(6,436)	(24,985)
Accrued compensation	(33,153)	(7,648)
Deferred revenue	8,151	(6,796)
Customer contract deposits	7,849	(17,519)
Other assets and liabilities, net	(46,657)	(5,209)
Net cash provided by operating activities	323,423	257,505
Cash flows relating to investing activities
Acquisition of businesses and assets, net of cash acquired	(5,479)	(50,166)
Capital expenditures	(118,630)	(174,258)
Purchases of investments and contributions to venture capital investments	(35,538)	(22,689)
Proceeds from sale of investments	12,359	2,943
Other, net	(370)	(1,057)
Net cash used in investing activities	(147,658)	(245,227)
Cash flows relating to financing activities
Proceeds from long-term debt and revolving credit facility	741,200	281,796
Proceeds from exercises of stock options	22,331	15,719
Payments on long-term debt, revolving credit facility, and finance lease obligations	(987,344)	(317,049)
Purchase of treasury stock	(18,265)	(23,978)
Payments of contingent consideration	0	(2,711)
Purchases of additional equity interests, net	(12,000)	0
Other, net	(13,434)	0
Net cash used in financing activities	(267,512)	(46,223)
Effect of exchange rate changes on cash, cash equivalents, and restricted cash	(11,729)	1,508
Net change in cash, cash equivalents, and restricted cash	(103,476)	(32,437)
Cash, cash equivalents, and restricted cash, beginning of period	284,480	241,214
Cash, cash equivalents, and restricted cash, end of period	$ 181,004	$ 208,777

v3.24.2.u1

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY AND REDEEMABLE NONCONTROLLING INTERESTS (UNAUDITED) - USD ($) shares in Thousands, $ in Thousands	Total	Total Charles River Laboratories, Inc. Equity	Common Stock	Additional Paid-In Capital	Retained Earnings	Accumulated Other Comprehensive Income (Loss)	Treasury Stock	Noncontrolling Interest
Beginning balance at Dec. 31, 2022	$ 42,427
Increase (Decrease) in Temporary Equity
Net income	322
Other comprehensive (loss), net of tax	186
Ending balance at Apr. 01, 2023	42,935
Beginning balance (in shares) at Dec. 31, 2022			50,944
Beginning balance at Dec. 31, 2022	2,981,078	$ 2,976,293	$ 509	$ 1,804,940	$ 1,432,901	$ (262,057)	$ 0	$ 4,785
Beginning balance (in shares) at Dec. 31, 2022							0
Increase (Decrease) in Stockholders' Equity
Net income	103,632	103,131			103,131			501
Other comprehensive (loss), net of tax	22,933	22,933				22,933
Issuance of stock under employee compensation plans (in shares)			316
Issuance of stock under employee compensation plans	11,792	11,792	$ 3	11,789
Purchase of treasury shares (in shares)							78
Purchase of treasury shares	(19,012)	(19,012)					$ (19,012)
Stock-based compensation	13,460	13,460		13,460
Ending balance (in shares) at Apr. 01, 2023			51,260
Ending balance at Apr. 01, 2023	3,113,883	3,108,597	$ 512	1,830,189	1,536,032	(239,124)	$ (19,012)	5,286
Ending balance (in shares) at Apr. 01, 2023							78
Increase (Decrease) in Temporary Equity
Net income	1,857
Other comprehensive (loss), net of tax	(2,345)
Ending balance at Jul. 01, 2023	42,447
Increase (Decrease) in Stockholders' Equity
Net income	97,586	97,020			97,020			566
Other comprehensive (loss), net of tax	30,855	30,855				30,855
Issuance of stock under employee compensation plans (in shares)			110
Issuance of stock under employee compensation plans	3,927	3,927	$ 1	3,926
Purchase of treasury shares (in shares)							26
Purchase of treasury shares	(4,966)	(4,966)					$ (4,966)
Stock-based compensation	16,270	16,270		16,270
Ending balance (in shares) at Jul. 01, 2023			51,370
Ending balance at Jul. 01, 2023	3,257,555	3,251,703	$ 513	1,850,385	1,633,052	(208,269)	$ (23,978)	5,852
Ending balance (in shares) at Jul. 01, 2023							104
Beginning balance at Dec. 30, 2023	56,722
Increase (Decrease) in Temporary Equity
Net income	1,201
Other comprehensive (loss), net of tax	(2,763)
Adjustment of redeemable noncontrolling interests to redemption value	4,807
Dividends to noncontrolling interests	(2,192)
Ending balance at Mar. 30, 2024	$ 57,775
Beginning balance (in shares) at Dec. 30, 2023	51,338		51,338
Beginning balance at Dec. 30, 2023	$ 3,602,276	3,596,882	$ 513	1,905,578	1,887,218	(196,427)	$ 0	5,394
Beginning balance (in shares) at Dec. 30, 2023	0						0
Increase (Decrease) in Stockholders' Equity
Net income	$ 73,281	72,960			72,960			321
Other comprehensive (loss), net of tax	(53,492)	(53,492)				(53,492)
Adjustment of redeemable noncontrolling interests to redemption value	(4,807)	(4,807)		(4,406)	(401)
Dividends to noncontrolling interests	0
Issuance of stock under employee compensation plans (in shares)			214
Issuance of stock under employee compensation plans	21,505	21,505	$ 2	21,503
Purchase of treasury shares (in shares)							42
Purchase of treasury shares	(9,351)	(9,351)					$ (9,351)
Stock-based compensation	16,738	16,738		16,738
Ending balance (in shares) at Mar. 30, 2024			51,552
Ending balance at Mar. 30, 2024	3,646,150	3,640,435	$ 515	1,939,413	1,959,777	(249,919)	$ (9,351)	5,715
Ending balance (in shares) at Mar. 30, 2024							42
Beginning balance at Dec. 30, 2023	56,722
Ending balance at Jun. 29, 2024	$ 46,076
Beginning balance (in shares) at Dec. 30, 2023	51,338		51,338
Beginning balance at Dec. 30, 2023	$ 3,602,276	3,596,882	$ 513	1,905,578	1,887,218	(196,427)	$ 0	5,394
Beginning balance (in shares) at Dec. 30, 2023	0						0
Ending balance (in shares) at Jun. 29, 2024	51,613		51,696
Ending balance at Jun. 29, 2024	$ 3,727,018	3,722,729	$ 517	1,956,629	2,053,557	(269,709)	$ (18,265)	4,289
Ending balance (in shares) at Jun. 29, 2024	83						83
Beginning balance at Mar. 30, 2024	$ 57,775
Increase (Decrease) in Temporary Equity
Net income	(332)
Other comprehensive (loss), net of tax	85
Adjustment of redeemable noncontrolling interests to redemption value	496
Dividends to noncontrolling interests	0
Purchase of remaining equity interest of other redeemable noncontrolling interest	(12,000)
Adjustment of purchase price of Noveprim redeemable noncontrolling interest	52
Ending balance at Jun. 29, 2024	46,076
Beginning balance (in shares) at Mar. 30, 2024			51,552
Beginning balance at Mar. 30, 2024	3,646,150	3,640,435	$ 515	1,939,413	1,959,777	(249,919)	$ (9,351)	5,715
Beginning balance (in shares) at Mar. 30, 2024							42
Increase (Decrease) in Stockholders' Equity
Net income	94,593	94,081			94,081			512
Other comprehensive (loss), net of tax	(19,790)	(19,790)				(19,790)
Adjustment of redeemable noncontrolling interests to redemption value	(496)	(496)		(195)	(301)
Dividends to noncontrolling interests	(1,938)							(1,938)
Issuance of stock under employee compensation plans (in shares)			144
Issuance of stock under employee compensation plans	826	826	$ 2	824
Purchase of treasury shares (in shares)							41
Purchase of treasury shares	(8,914)	(8,914)					$ (8,914)
Stock-based compensation	$ 16,587	16,587		16,587
Ending balance (in shares) at Jun. 29, 2024	51,613		51,696
Ending balance at Jun. 29, 2024	$ 3,727,018	$ 3,722,729	$ 517	$ 1,956,629	$ 2,053,557	$ (269,709)	$ (18,265)	$ 4,289
Ending balance (in shares) at Jun. 29, 2024	83						83

v3.24.2.u1

BASIS OF PRESENTATION	6 Months Ended
	Jun. 29, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BASIS OF PRESENTATION	BASIS OF PRESENTATION The accompanying condensed consolidated financial statements are unaudited and have been prepared by Charles River Laboratories International, Inc. (the Company) in accordance with accounting principles generally accepted in the United States (U.S. GAAP) and pursuant to the rules and regulations of the Securities and Exchange Commission (SEC). The year-end condensed consolidated balance sheet data was derived from the Company’s audited consolidated financial statements, but does not include all disclosures required by U.S. GAAP. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K for fiscal year 2023 as filed with the SEC on February 14, 2024. Certain reclassifications of prior year amounts have been made to conform to the current year presentation. The unaudited condensed consolidated financial statements, in the opinion of management, reflect all normal and recurring adjustments necessary for a fair statement of the Company’s financial position and results of operations. Use of Estimates The preparation of unaudited condensed consolidated financial statements in accordance with U.S. GAAP requires that the Company make estimates and judgments that may affect the reported amounts of assets, liabilities, revenues, expenses and related disclosure of contingent assets and liabilities. On an on-going basis, the Company evaluates its estimates, judgments, and methodologies. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ from these estimates under different assumptions or conditions. Changes in estimates are reflected in reported results in the period in which they become known. Newly Issued Accounting Pronouncements In November 2023, the FASB issued ASU 2023-07, “Improvements to Reportable Segment Disclosures (Topic 280)”. ASU 2023-07 modifies reportable segment disclosure requirements, primarily through enhanced disclosures about segment expenses categorized as significant or regularly provided to the Chief Operating Decision Maker (CODM). In addition, the amendments enhance interim disclosure requirements, clarify circumstances in which an entity can disclose multiple segment measures of profit or loss, and contain other disclosure requirements. The purpose of the amendments is to enable investors to better understand an entity’s overall performance and assess potential future cash flows. This ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted and the amendments in this update are required to be applied on a retrospective basis. The Company is currently evaluating the impact this new standard will have on the related disclosures in the annual consolidated financial statements, but does not believe there will be a material impact. In December 2023, the FASB issued ASU 2023-09, “Improvements to Income Tax Disclosures (Topic 740)”. ASU 2023-09 requires enhanced disclosures on income taxes paid, adds disaggregation of continuing operations before income taxes between foreign and domestic earnings and defines specific categories for the reconciliation of jurisdictional tax rate to effective tax rate. This ASU is effective for fiscal years beginning after December 15, 2024, and can be applied on a prospective basis. The Company is currently evaluating the impact this new standard will have on the related disclosures on the consolidated financial statements. Summary of Significant Accounting Policies The Company’s significant accounting policies are described in Note 1, “Description of Business and Summary of Significant Accounting Policies” in the Company’s Annual Report on Form 10-K for fiscal year 2023 as filed with the SEC on February 14, 2024. Consolidation The Company’s unaudited condensed consolidated financial statements reflect its financial statements and those of its subsidiaries in which the Company holds a controlling financial interest. For consolidated entities in which the Company owns or is exposed to less than 100% of the economics, the Company records net income (loss) attributable to noncontrolling interests in its unaudited condensed consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Redeemable noncontrolling interests, where the noncontrolling interest holders have the ability to require the Company to purchase the remaining interests, are classified in the mezzanine section of the unaudited condensed consolidated balance sheets, which is presented above the equity section and below liabilities. Intercompany balances and transactions are eliminated in consolidation. The Company’s fiscal year is typically based on 52-weeks, with each quarter composed of 13 weeks ending on the last Saturday on, or closest to, March 31, June 30, September 30, and December 31. A 53rd week in the fourth quarter of the fiscal year is occasionally necessary to align with a December 31 calendar year-end. Segment Reporting The Company reports its results in three reportable segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The Company’s RMS reportable segment includes the Research Models, Research Model Services, and Cell Solutions businesses. Research Models includes the commercial production and sale of small research models, as well as the supply of large research models. Research Model Services includes: Insourcing Solutions (IS), which provides colony management of clients’ research operations (including recruitment, training, staffing, and management services) within the clients’ facilities and utilizing the Charles River Accelerator and Development Lab (CRADL™) offering, which provides vivarium space to clients, Genetically Engineered Models and Services (GEMS), which performs contract breeding and other services associated with genetically engineered models, and Research Animal Diagnostic Services (RADS), which provides health monitoring and diagnostics services related to research models; and Cell Solutions, which supplies controlled, consistent, customized primary cells and blood components derived from normal and mobilized peripheral blood and bone marrow. The Company’s DSA reportable segment includes two businesses: Discovery Services and Safety Assessment. The Company provides regulated and non-regulated DSA services to support the research, development, and regulatory-required safety testing of potential new drugs, including therapeutic discovery and optimization plus in vitro and in vivo studies, laboratory support services, and strategic non-clinical consulting and program management to support product development. The Company’s Manufacturing reportable segment includes Microbial Solutions, which provides in vitro (non-animal) lot-release testing products, microbial detection products, and species identification services and Biologics Solutions (Biologics), which performs specialized testing of biologics (Biologics Testing Solutions) as well as contract development and manufacturing products and services (CDMO).

v3.24.2.u1

ACQUISITIONS AND DIVESTITURES	6 Months Ended
	Jun. 29, 2024
Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]
ACQUISITIONS AND DIVESTITURES	ACQUISITIONS AND DIVESTITURES Fiscal 2023 Acquisition Noveprim Group On November 30, 2023, the Company completed the acquisition of an additional 41% equity interest of Noveprim Group (Noveprim), a leading supplier of non-human primates (NHPs) located in Mauritius, resulting in a 90% controlling interest. The Company had previously acquired a 49% equity interest in 2022 for $90.0 million plus additional contingent payments up to $5.0 million based on future performance. The total consideration allocable to the Noveprim acquisition is $392.4 million, which includes $144.6 million additional cash paid for the 41% equity interest, elimination of historical activity and intercompany balances of $209.5 million which includes a remeasurement gain on the 49% equity investment of $113.0 million, contingent consideration of $33.3 million, deferred purchase price of $12.0 million payable from 2024 through 2027, offset by estimated post-closing adjustments for working capital of $7.0 million. The purchase price reflected a preliminary agreement with seller on working capital and debt, which was adjusted from $13.8 million to $7.0 million during the quarter ended June 29, 2024. As a result of measurement period adjustments to the purchase price, goodwill and remeasurement gains on the previous 49% equity investment for the quarter ended June 29, 2024, were increased by $17.6 million and $9.8 million, respectively. The contingent consideration fair value is estimated using a Monte Carlo Simulation model and the maximum contingent contractual payments are up to $55.0 million based on future performance and milestone achievements in fiscal years 2023 through 2025. The Company has the call option right to purchase the remaining 10% equity interest up until one month after the sixth anniversary of closing the 41% equity interest. On the first anniversary of the expiration of the call option, a 12-month put option will be triggered giving the seller the right to require the Company to acquire the remaining shares of the seller. The redemption price for the call/put is fixed and ranges from $47.0 million to $54.0 million depending on when exercised. The noncontrolling interest is classified as a redeemable noncontrolling interest in the mezzanine section of the unaudited condensed consolidated balance sheet. The acquisition was funded through a combination of available cash and proceeds from the Company’s Credit Facility. This business is reported as part of the Company’s DSA reportable segment for NHPs vertically integrated into the DSA supply chain and the RMS reportable segment for those NHPs sold to third party customers. The Company incurred transaction and integration costs in connection with the acquisition of $0.7 million and $1.4 million for the three months ended June 29, 2024 and July 1, 2023, respectively, which was primarily included in Selling, general and administrative expenses within the unaudited condensed consolidated statements of income. The Company incurred transaction and integration costs in connection with the acquisition of $0.9 million and $2.2 million for six months ended June 29, 2024 and July 1, 2023, respectively, which was primarily included in Selling, general and administrative expenses within the unaudited condensed consolidated statements of income. SAMDI Tech, Inc. On January 27, 2023, the Company acquired SAMDI Tech, Inc., (SAMDI), a leading provider of high-quality, label-free high-throughput screening (HTS) solutions for drug discovery research. The acquisition of SAMDI will provide clients with seamless access to the premier, label-free HTS MS platform and create a comprehensive, library of drug discovery solutions. The purchase price of SAMDI was $62.8 million, net of $0.4 million in cash, inclusive of a 20% strategic equity interest previously owned by the Company of $12.6 million. The acquisition was funded through a combination of available cash and proceeds from the Company’s Credit Facility. This business is reported as part of the Company’s DSA reportable segment. No significant transaction and integration costs were incurred with the acquisition for the three and six months ended June 29, 2024. The Company incurred transaction and integration costs in connection with the acquisition of $0.3 million for the three and six months ended July 1, 2023, respectively, which was primarily included in Selling, general and administrative expenses within the unaudited condensed consolidated statements of income. Purchase price information The purchase price allocation was as follows: Noveprim Group(1) SAMDI Tech, Inc. November 30, 2023 January 27, 2023 (in thousands) Trade receivables $ 1,308  $ 513  Inventories 66,500  —  Other current assets (excluding cash) 3,261  75  Property, plant and equipment 36,154  593  Operating lease right-of-use asset, net 104  —  Goodwill (2) 190,024  37,129  Definite-lived intangible assets 9,500  33,070  Other long-term assets (3) 167,907  6  Deferred revenue —  (43) Other current liabilities (16,268) (351) Operating lease right-of-use liabilities (Long-term) (97) —  Deferred tax liabilities (12,984) (8,191) Other long-term liabilities (7,579) —  Redeemable noncontrolling interest (4) (45,426) —  Total purchase price allocation $ 392,404  $ 62,801  (1) Purchase price allocation is preliminary and subject to change as additional information becomes available concerning the fair value and tax basis of the assets acquired and liabilities assumed, including certain contracts, obligations, and finalization of any working capital adjustments. Any additional adjustments to the purchase price allocation will be made as soon as practicable but no later than one year from the date of acquisition. (2) The goodwill resulting from these transactions is primarily attributable to the potential growth of the Company’s segments from new customers introduced to the acquired businesses or synergies to be realized from acquiring an internal supplier servicing the DSA business and the assembled workforce of the acquirees, thus is not deductible for tax purposes. (3) Other long-term assets acquired from the Noveprim acquisition include $167.8 million of biological assets, which will be amortized over an estimated eight-year useful life. (4) Refer to Note 12. Equity and Noncontrolling Interests for further a description of the 10% noncontrolling interest fair value. The definite-lived intangible assets acquired were as follows: Noveprim Group SAMDI Tech, Inc. Definite-Lived Intangible Assets (in thousands) Client relationships $ —  $ 23,400  Other intangible assets 9,500  9,670  Total definite-lived intangible assets $ 9,500  $ 33,070  Weighted Average Amortization Life (in years) Client relationships —  15 Other intangible assets 7 7 Total definite-lived intangible assets 7 12

v3.24.2.u1

REVENUE FROM CONTRACTS WITH CUSTOMERS	6 Months Ended
	Jun. 29, 2024
Revenue from Contract with Customer [Abstract]
REVENUE FROM CONTRACTS WITH CUSTOMERS	REVENUE FROM CONTRACTS WITH CUSTOMERS Disaggregation of Revenue The following table disaggregates the Company’s revenue by major business line and timing of transfer of products or services: Three Months Ended Six Months Ended June 29, 2024 July 1, 2023 June 29, 2024 July 1, 2023 (in thousands) Timing of Revenue Recognition: RMS Services and products transferred over time $ 95,299  $ 94,458  $ 192,348  $ 188,097  Services and products transferred at a point in time 111,090  115,490  234,948  221,617  Total RMS revenue 206,389  209,948  427,296  409,714  DSA Services and products transferred over time 626,785  662,653  1,230,910  1,324,489  Services and products transferred at a point in time 634  804  1,961  1,321  Total DSA revenue 627,419  663,457  1,232,871  1,325,810  Manufacturing Services and products transferred over time 104,481  100,460  204,539  186,546  Services and products transferred at a point in time 87,828  86,072  172,971  167,240  Total Manufacturing revenue 192,309  186,532  377,510  353,786  Total revenue $ 1,026,117  $ 1,059,937  $ 2,037,677  $ 2,089,310  Contract Balances from Contracts with Customers The following table provides information about client receivables, contract assets, and contract liabilities from contracts with customers: June 29, 2024 December 30, 2023 (in thousands) Assets from contracts with customers Client receivables $ 568,283  $ 578,077  Unbilled revenue 218,889  228,020  Total 787,172  806,097  Less: Allowance for credit losses (24,951) (25,722) Trade receivables and contract assets, net $ 762,221  $ 780,375  Liabilities from contracts with customers Current deferred revenue $ 247,177  $ 241,820  Long-term deferred revenue (included in Other long-term liabilities) 29,139  30,919  Customer contract deposits (included in Other current liabilities) 92,032  85,554  Approximately 85% of unbilled revenue as of December 30, 2023, which was $228 million, was billed during the six months ended June 29, 2024. Approximately 85% of unbilled revenue as of December 31, 2022, which was $204 million, was billed during the six months ended July 1, 2023. Approximately 70% of contract liabilities as of December 30, 2023, which was $273 million, were recognized as revenue during the six months ended June 29, 2024. Approximately 75% of contract liabilities as of December 31, 2022, which was $290 million, were recognized as revenue during the six months ended July 1, 2023. When the Company does not have the unconditional right to advanced billings, both advanced client payments and unpaid advanced client billings are excluded from deferred revenue, with the advanced billings also being excluded from client receivables. The Company excluded approximately $46 million and $41 million of unpaid advanced client billings from both client receivables and deferred revenue in the accompanying unaudited condensed consolidated balance sheets as of June 29, 2024 and December 30, 2023, respectively. Allowance for Credit Losses The following is a summary of the activity of the Company’s allowance for credit losses: Six Months Ended June 29, 2024 July 1, 2023 (in thousands) Beginning balance $ 25,722  $ 11,278  Provisions 4,719  9,849  Reductions (5,490) (3,087) Ending balance $ 24,951  $ 18,040  Net provision expenses were $4.1 million and $9.2 million during the six months ended June 29, 2024 and July 1, 2023, respectively and include recoveries of balances previously written off, which are excluded from the table above. Transaction Price Allocated to Future Performance Obligations The Company discloses the aggregate amount of transaction price that is allocated to performance obligations that have not yet been satisfied as of June 29, 2024. Excluded from the disclosure is the value of unsatisfied performance obligations for contracts with an original expected length of one year or less, contracts for which revenue is recognized at the amount to which the Company has the right to invoice for services performed, and service revenue recognized in accordance with ASC 842, “Leases”. The aggregate amount of transaction price allocated to the remaining performance obligations for all open customer contracts as of June 29, 2024 was $856.6 million. The Company will recognize revenues for these performance obligations as they are satisfied, approximately 50% of which is expected to occur within the next twelve months and the remainder recognized thereafter during the remaining contract term. Other Performance Obligations As part of the Company’s service offerings, the Company has identified performance obligations related to leasing Company owned assets. In certain arrangements, customers obtain substantially all of the economic benefits of the identified assets, which may include manufacturing suites and related equipment, and have the right to direct the assets’ use over the term of the contract. The associated revenue is recognized on a straight-line basis over the term of the lease, which is generally less than one year. Three Months Ended Six Months Ended June 29, 2024 July 1, 2023 June 29, 2024 July 1, 2023 (in thousands) Affected Line Item in the Unaudited Condensed Consolidated Statements of Income Lease revenue $ 16,716  $ 23,891  $ 37,690  $ 47,981  Service revenue

v3.24.2.u1

SEGMENT AND GEOGRAPHIC INFORMATION	6 Months Ended
	Jun. 29, 2024
Segment Reporting [Abstract]
SEGMENT AND GEOGRAPHIC INFORMATION	SEGMENT AND GEOGRAPHIC INFORMATION The Company operates in three reportable segments, RMS, DSA and Manufacturing. Asset information on a reportable segment basis is not disclosed as this information is not separately identified and internally reported to the Company’s Chief Operating Decision Maker (CODM). The following table presents the results of operations by reportable segment: Three Months Ended Six Months Ended June 29, 2024 July 1, 2023 June 29, 2024 July 1, 2023 (in thousands) RMS     Revenue $ 206,389  $ 209,948  $ 427,296  $ 409,714  Cost of revenue (excluding amortization of intangible assets) 142,942  127,888  283,867  254,692  Selling, general and administrative 27,597  27,653  58,490  54,711  Amortization of intangible assets 5,902  5,489  11,842  10,984  Operating income $ 29,948  $ 48,918  $ 73,097  $ 89,327  DSA Revenue $ 627,419  $ 663,457  $ 1,232,871  $ 1,325,810  Cost of revenue (excluding amortization of intangible assets) 418,964  420,551  836,876  832,074  Selling, general and administrative 54,479  63,709  111,338  125,707  Amortization of intangible assets 15,600  17,659  31,442  35,060  Operating income $ 138,376  $ 161,538  $ 253,215  $ 332,969  Manufacturing Revenue $ 192,309  $ 186,532  $ 377,510  $ 353,786  Cost of revenue (excluding amortization of intangible assets) 110,498  112,522  218,378  225,914  Selling, general and administrative 33,813  38,481  66,660  78,218  Amortization of intangible assets 10,768  11,126  21,561  23,145  Operating income $ 37,230  $ 24,403  $ 70,911  $ 26,509  Unallocated Corporate Selling, general and administrative $ 53,902  $ 69,914  $ 119,594  $ 115,968  Operating income (1) $ (53,902) $ (69,914) $ (119,594) $ (115,968) Consolidated Revenue $ 1,026,117  $ 1,059,937  $ 2,037,677  $ 2,089,310  Cost of revenue (excluding amortization of intangible assets) 672,404  660,960  1,339,121  1,312,679  Selling, general and administrative 169,791  199,758  356,082  374,604  Amortization of intangible assets 32,270  34,274  64,845  69,190  Operating income $ 151,652  $ 164,945  $ 277,629  $ 332,837  (1) Operating income for unallocated corporate consists of costs associated with departments such as senior executives, corporate accounting, legal, tax, human resources, treasury, and investor relations. Capital expenditures and depreciation and amortization (related to both intangible assets and certain assets acquired in business combinations) by reportable segment are as follows: RMS DSA Manufacturing Unallocated Corporate Consolidated (in thousands) Capital Expenditures Three Months Ended: June 29, 2024 $ 9,313  $ 19,444  $ 10,583  $ 146  $ 39,486  July 1, 2023 7,493  48,326  10,862  702  67,383  Six Months Ended: June 29, 2024 $ 29,357  $ 68,403  $ 19,445  $ 1,425  $ 118,630  July 1, 2023 26,577  113,510  32,600  1,571  174,258  Depreciation and amortization Three Months Ended: June 29, 2024 $ 16,538  $ 47,729  $ 20,073  $ 1,742  $ 86,082  July 1, 2023 13,949  43,124  19,523  1,075  77,671  Six Months Ended: June 29, 2024 $ 34,661  $ 93,518  $ 39,878  $ 3,382  $ 171,439  July 1, 2023 27,438  85,574  39,607  2,121  154,740  Revenue by geographic area is as follows: U.S. Europe Canada Asia Pacific Other Consolidated (in thousands) Three Months Ended: June 29, 2024 $ 571,427  $ 271,377  $ 125,244  $ 50,387  $ 7,682  $ 1,026,117  July 1, 2023 606,775  272,976  117,647  59,864  2,675  1,059,937  Six Months Ended: June 29, 2024 $ 1,133,744  $ 547,696  $ 235,645  $ 96,159  $ 24,433  $ 2,037,677  July 1, 2023 1,212,216  540,679  228,253  102,677  5,485  2,089,310  Included in the Other category above are operations located in Brazil, Israel, and Mauritius. Revenue represents sales originating in entities physically located in the identified geographic area. Long-lived assets by geographic area are as follows: U.S. Europe Canada Asia Pacific Other Consolidated (in thousands) Long-lived assets June 29, 2024 $ 950,254  $ 405,429  $ 153,945  $ 68,868  $ 35,399  $ 1,613,895  December 30, 2023 964,176  407,375  157,483  74,605  36,102  1,639,741  Long-lived assets consist of property, plant, and equipment, net.

v3.24.2.u1

SUPPLEMENTAL CASH FLOW INFORMATION	6 Months Ended
	Jun. 29, 2024
Supplemental Cash Flow Information [Abstract]
SUPPLEMENTAL CASH FLOW INFORMATION	SUPPLEMENTAL CASH FLOW INFORMATION Six Months Ended June 29, 2024 July 1, 2023 (in thousands) Cash paid for income taxes $ 71,722  $ 61,816  Cash paid for interest 65,630  66,563  Non-cash investing activities: Purchases of Property, plant and equipment included in Accounts payable and Accrued liabilities $ 25,278  $ 47,850  Assets acquired under finance leases 3,159  154  Cash, cash equivalents and restricted cash is included in the accompanying unaudited balance sheet as follows: June 29, 2024 December 30, 2023 (in thousands) Supplemental cash flow information: Cash and cash equivalents $ 179,213  $ 276,771  Restricted cash included in Other current assets 325  5,803  Restricted cash included in Other assets 1,466  1,906  Cash, cash equivalents, and restricted cash, end of period $ 181,004  $ 284,480

v3.24.2.u1

INVENTORY	6 Months Ended
	Jun. 29, 2024
Inventory Disclosure [Abstract]
INVENTORY	INVENTORY Inventories The composition of inventories is as follows: June 29, 2024 December 30, 2023 (in thousands) Raw materials and supplies $ 43,238  $ 42,296  Work in process 57,923  59,727  Finished products 247,950  278,236  Inventories $ 349,111  $ 380,259  Inventory step up amortization expense incurred for the three and six months ended June 29, 2024 was $3.5 million and $10.6 million, respectively.

v3.24.2.u1

PROPERTY, PLANT AND EQUIPMENT, NET	6 Months Ended
	Jun. 29, 2024
Property, Plant and Equipment [Abstract]
PROPERTY, PLANT AND EQUIPMENT, NET	PROPERTY, PLANT AND EQUIPMENT, NET The composition of property, plant and equipment, net is as follows: June 29, 2024 December 30, 2023 (in thousands) Land $ 78,812  $ 79,546  Buildings (1) 1,061,408  1,053,915  Machinery and equipment (1) 1,007,210  984,867  Leasehold improvements 381,879  366,556  Furniture and fixtures 32,060  31,284  Computer hardware and software (1) 259,889  254,413  Vehicles (1) 7,149  6,746  Construction in progress 182,823  197,723  Total 3,011,230  2,975,050  Less: Accumulated depreciation (1,397,335) (1,335,309) Property, plant and equipment, net $ 1,613,895  $ 1,639,741  (1) These balances include assets under finance leases. Depreciation expense in the three months ended June 29, 2024 and July 1, 2023 was $47.6 million and $43.4 million, respectively. Depreciation expense in the six months ended June 29, 2024 and July 1, 2023 was $93.3 million and $85.5 million, respectively.

v3.24.2.u1

VENTURE CAPITAL AND STRATEGIC EQUITY INVESTMENTS	6 Months Ended
	Jun. 29, 2024
Equity Method Investments and Joint Ventures [Abstract]
VENTURE CAPITAL AND STRATEGIC EQUITY INVESTMENTS	VENTURE CAPITAL AND STRATEGIC EQUITY INVESTMENTS Venture capital investments are summarized below: Six Months Ended June 29, 2024 July 1, 2023 (in thousands) Beginning balance $ 121,158  $ 129,012  Capital contributions 6,479  8,702  Distributions (16,100) (9,679) Gains (losses) 1,789  (8,429) Foreign currency translation (249) 466  Ending balance $ 113,077  $ 120,072  The Company also invests, with minority positions, directly in equity of predominantly privately held companies. Strategic investments are summarized below: Six Months Ended June 29, 2024 July 1, 2023 (in thousands) Beginning balance $ 122,653  $ 182,590  Purchase of investments 2,140  13,710  Distributions —  (4,146) Gain (loss) (5,265) 3,253  Reduction for acquisition of entity (1) —  (12,635) Foreign currency translation (746) (2,563) Ending balance $ 118,782  $ 180,209  (1) Refer to Note 2. Acquisitions for further discussion on the acquisition of SAMDI.

v3.24.2.u1

FAIR VALUE	6 Months Ended
	Jun. 29, 2024
Fair Value Disclosures [Abstract]
FAIR VALUE	FAIR VALUE Assets and liabilities measured at fair value on a recurring basis are summarized below:   June 29, 2024 Level 1 Level 2 Level 3 Total Current assets measured at fair value: (in thousands) Cash equivalents $ —  $ 7,257  $ —  $ 7,257  Term deposit —  26,983  —  26,983  Other assets: Life insurance policies —  45,210  —  45,210  Interest rate swap —  1,338  —  1,338  Total assets measured at fair value $ —  $ 80,788  $ —  $ 80,788  Other long-term liabilities measured at fair value: Contingent consideration $ —  $ —  $ 38,335  $ 38,335  Total liabilities measured at fair value $ —  $ —  $ 38,335  $ 38,335  The Company recognizes transfers between levels within the fair value hierarchy, if any, at the end of each quarter. During the six months ended June 29, 2024, there were no transfers between levels.   December 30, 2023 Level 1 Level 2 Level 3 Total Current assets measured at fair value: (in thousands) Cash equivalents $ —  $ 29  $ —  $ 29  Other assets: Life insurance policies —  40,912  —  40,912  Interest rate swap —  966  —  966  Total assets measured at fair value $ —  $ 41,907  $ —  $ 41,907  Other long-term liabilities measured at fair value Contingent consideration $ —  $ —  $ 33,265  $ 33,265  Total liabilities measured at fair value $ —  $ —  $ 33,265  $ 33,265  During the year ended December 30, 2023, there were no transfers between levels. Contingent Consideration The following table provides a rollforward of the contingent consideration related to the Company’s acquisitions. Six Months Ended June 29, 2024 July 1, 2023 (in thousands) Beginning balance $ 33,265  $ 13,431  Payments —  (15,130) Total gains or losses (realized/unrealized): Adjustment of previously recorded contingent liability 5,070  1,810  Foreign currency translation —  (111) Ending balance $ 38,335  $ —  The Company estimates the fair value of contingent consideration obligations through valuation models, such as probability-weighted and option pricing models, which incorporate probability adjusted assumptions and simulations related to the achievement of the milestones and the likelihood of making related payments. The unobservable inputs used in the fair value measurements include the probabilities of successful achievement of certain financial targets, forecasted results or targets, volatility, and discount rates. The remaining maximum potential payments are approximately $55 million, of which the value accrued as of June 29, 2024 is $38 million as the probability of achieving the maximum target is estimated to be 70%. The volatility and weighted average cost of capital is approximately 5% and 8%, respectively. Increases or decreases in these assumptions may result in a higher or lower fair value measurement, respectively. Cash Flow Hedge The Company is exposed to market fluctuations in interest rates as well as variability in foreign exchange rates. The Company has an interest rate swap with a notional amount of $500 million maturing November 2, 2024 to manage interest rate fluctuation related to floating rate borrowings under the Credit Facility, at a fixed rate of 4.65%. Debt Instruments The book value of the Company’s revolving loans, which are variable rate loans carried at amortized cost, approximates the fair value based on current market pricing of similar debt. As the fair value is based on significant other observable inputs, including current interest and foreign currency exchange rates, it is deemed to be Level 2 within the fair value hierarchy. The book value of the Company’s Senior Notes are fixed rate obligations carried at amortized cost. Fair value is based on quoted market prices as well as borrowing rates available to the Company. As the fair value is based on significant other observable outputs, it is deemed to be Level 2 within the fair value hierarchy. The book value and fair value of the Company’s Senior Notes is summarized below: June 29, 2024 December 30, 2023 Book Value Fair Value Book Value Fair Value (in thousands) 4.25% Senior Notes due 2028 $ 500,000  $ 468,750  $ 500,000  $ 478,100  3.75% Senior Notes due 2029 500,000  453,750  500,000  458,100  4.00% Senior Notes due 2031 500,000  445,000  500,000  449,350

v3.24.2.u1

GOODWILL AND INTANGIBLE ASSETS	6 Months Ended
	Jun. 29, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
GOODWILL AND INTANGIBLE ASSETS	GOODWILL AND INTANGIBLE ASSETS Goodwill The following table provides a rollforward of the Company’s goodwill: RMS DSA (1) Manufacturing Total (in thousands) December 30, 2023 $ 497,474  $ 1,662,434  $ 935,137  $ 3,095,045  Acquisitions —  17,675  —  17,675  Foreign exchange (536) (29,251) (3,240) (33,027) June 29, 2024 $ 496,938  $ 1,650,858  $ 931,897  $ 3,079,693  (1) DSA includes accumulated impairment losses of $1 billion, which were recognized in fiscal years 2008 and 2010. The decrease in goodwill during the six months ended June 29, 2024 is related to foreign exchange in the DSA and Manufacturing reportable segments, partially offset by measurement period adjustments related to the acquisition of Noveprim in the DSA reportable segment. Intangible Assets, Net The following table displays intangible assets, net by major class:   June 29, 2024 December 30, 2023 Gross Accumulated Amortization Net Gross Accumulated Amortization Net (in thousands) Client relationships $ 1,518,194  $ (766,261) $ 751,933  $ 1,528,780  $ (721,322) $ 807,458  Technology 140,737  (114,410) 26,327  142,190  (111,764) 30,426  Trademarks and trade names 11,849  (5,098) 6,751  11,878  (4,568) 7,310  Backlog 3,100  (2,792) 308  3,100  (2,177) 923  Other 42,866  (28,056) 14,810  43,611  (25,677) 17,934  Intangible assets $ 1,716,746  $ (916,617) $ 800,129  $ 1,729,559  $ (865,508) $ 864,051  The decrease in intangible assets, net during the six months ended June 29, 2024 related to normal amortization over the useful lives. Amortization expense of definite-lived intangible assets for three months ended June 29, 2024 and July 1, 2023 was $32.3 million and $34.3 million, respectively. Amortization expense of definite-lived intangible assets for six months ended June 29, 2024 and July 1, 2023 was $64.8 million and $69.2 million, respectively.

v3.24.2.u1

DEBT AND OTHER FINANCING ARRANGEMENTS	6 Months Ended
	Jun. 29, 2024
Debt Disclosure [Abstract]
DEBT AND OTHER FINANCING ARRANGEMENTS	DEBT AND OTHER FINANCING ARRANGEMENTS Long-term debt, net and finance leases consists of the following: June 29, 2024 December 30, 2023 (in thousands) Revolving facility $ 879,498  $ 1,129,243  4.25% Senior Notes due 2028 500,000  500,000  3.75% Senior Notes due 2029 500,000  500,000  4.00% Senior Notes due 2031 500,000  500,000  Other debt 16,125  9,575  Finance leases 29,637  28,550  Total debt and finance leases 2,425,260  2,667,368  Less: Current portion of long-term debt 435  3,172  Current portion of finance leases 2,778  2,398  Current portion of long-term debt and finance leases 3,213  5,570  Long-term debt and finance leases 2,422,047  2,661,798  Debt discount and debt issuance costs (12,667) (14,651) Long-term debt, net and finance leases $ 2,409,380  $ 2,647,147  As of June 29, 2024 and December 30, 2023, the weighted average interest rate on the Company’s debt was 4.64% and 4.93%, respectively. Letters of Credit As of June 29, 2024 and December 30, 2023, the Company had $21.2 million and $21.6 million, respectively, in outstanding letters of credit.

v3.24.2.u1

EQUITY AND NONCONTROLLING INTERESTS	6 Months Ended
	Jun. 29, 2024
Equity [Abstract]
EQUITY AND NONCONTROLLING INTERESTS	EQUITY AND NONCONTROLLING INTERESTS Earnings Per Share The following table reconciles the numerator and denominator in the computations of basic and diluted earnings per share: Three Months Ended Six Months Ended June 29, 2024 July 1, 2023 June 29, 2024 July 1, 2023 (in thousands) Numerator:     Net income $ 94,261  $ 99,443  $ 168,743  $ 203,397  Less: Net income attributable to noncontrolling interests 180  2,423  1,702  3,246  Net income available to Charles River Laboratories International, Inc. 94,081  97,020  167,041  200,151  Calculation of net income per share attributable to common shareholders of Charles River Laboratories International, Inc. Net income available to Charles River Laboratories International, Inc. $ 94,081  $ 97,020  $ 167,041  $ 200,151  Less: Adjustment of redeemable noncontrolling interest (1) 301  —  702  —  Less: Incremental dividends attributable to noncontrolling interest holders (2) 3,792  —  9,022  —  Net income available to Charles River Laboratories International, Inc. common shareholders $ 89,988  $ 97,020  $ 157,317  $ 200,151  Denominator:     Weighted-average shares outstanding - Basic 51,551  51,216  51,494  51,157  Effect of dilutive securities: Stock options, restricted stock units and performance share units 295  251  316  225  Weighted-average shares outstanding - Diluted 51,846  51,467  51,810  51,382  Anti-dilutive common stock equivalents (3) 506  594  482  589  (1) Represents adjustments of redeemable noncontrolling interest that impact retained earnings. (2) Represents incremental undeclared dividends attributable to Noveprim noncontrolling interest holders who are entitled to preferential dividends for fiscal year 2024. (3) These common stock equivalents were outstanding for the periods presented, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect. Treasury Shares The Company’s Board of Directors had authorized a $1.3 billion stock repurchase program. As of June 29, 2024, the Company had $129.1 million remaining on the authorized stock repurchase program. On August 2, 2024, the Company’s Board of Directors approved a new stock repurchase authorization of $1.0 billion. This new authorization replaces the prior stock repurchase authorization of $1.3 billion that had $129.1 million remaining on the plan when it was terminated. The Company’s stock-based compensation plans permit the netting of common stock upon vesting of RSUs and PSUs in order to satisfy individual statutory tax withholding requirements. The Company acquired shares of approximately 0.1 million in the six months ended June 29, 2024 and six months ended July 1, 2023, for $18.3 million and $24.0 million, respectively, from such netting. Accumulated Other Comprehensive Income (Loss) Changes to each component of accumulated other comprehensive income (loss), net of income taxes, are as follows: Foreign Currency Translation Adjustment and Other Pension and Other Post-Retirement Benefit Plans Net Unrealized (Loss) Gain on Cash Flow Hedge Total (in thousands) December 30, 2023 $ (149,999) $ (47,167) $ 739  $ (196,427) Other comprehensive income (loss) before reclassifications (81,840) 686  372  (80,782) Net current period other comprehensive income (loss) (81,840) 686  372  (80,782) Income tax expense (benefit) (7,759) 170  89  (7,500) June 29, 2024 $ (224,080) $ (46,651) $ 1,022  $ (269,709) Redeemable Noncontrolling Interests Through June 29, 2024, the Company holds several redeemable noncontrolling interests. Since the Company has the right to purchase, and the noncontrolling interest holders have the right to require the Company to purchase the remaining interest, which represents a derivative embedded within the equity instrument, the noncontrolling interest is classified in the mezzanine section of the unaudited condensed consolidated balance sheets, which is presented above the equity section and below liabilities. The redeemable noncontrolling interests are measured at the greater of (i) the redemption amount or (ii) the historical value resulting from the original acquisition date fair value, increased or decreased for the noncontrolling interest’s share of net income (loss), equity capital contributions and distributions. The fair value of the redeemable noncontrolling interest is determined using the income approach, with key assumptions being projected cash flows and discount rates based on market participant’s weighted average cost of capital. To the extent redemption value exceeds carrying value, adjustments are recorded to additional paid-in capital, with any cumulative excess of redemption value over fair value recorded in retained earnings, which impacts net income available to common shareholders used in the calculation of earnings per common share. Noveprim The Company holds a 90% ownership interest in Noveprim. The Company has the right to purchase, and the noncontrolling interest holders have the right to sell, the remaining 10% equity interest at a fixed redemption value that ranges from $47.0 million to $54.0 million depending on when exercised. The Company has the call option right to purchase the remaining 10% equity up until one month after the sixth anniversary of closing the 41% equity stake (December 2029). On the first anniversary of the expiration of the call option (December 2030), a 12-month put option will be triggered giving the seller the right to require the Company to acquire the remaining shares of the seller for $54.0 million. Additionally, during fiscal year 2024 the 10% noncontrolling interest holders may receive a dividend disproportionate to their equity ownership, of which the fair value of $8.0 million as of the acquisition date was recorded within the redeemable noncontrolling interest. Through June 29, 2024, incremental dividends based on Noveprim statutory net income attributed to the redeemable noncontrolling interest holders of $9.0 million reduced net income available to common shareholders used in the calculation of earnings per common share. The redemption value is accreted to the put purchase price of $54.0 million using the interest method through December 2030. As of June 29, 2024, the redemption value of $46.1 million exceeded both the carrying value and fair value, resulting in both an adjustment to additional paid in capital of $1.8 million and an adjustment to retained earnings of $0.7 million, respectively. Other redeemable noncontrolling interest In 2019, the Company acquired an 80% equity interest in a subsidiary, which included a 20% redeemable noncontrolling interest. In June 2022, the Company purchased an additional 10% interest in the subsidiary for $15.0 million, resulting in a remaining noncontrolling interest of 10%. Beginning in 2024, the Company has the right to purchase, and the noncontrolling interest holders have the right to sell, the remaining 10% equity interest at its appraised value. The redemption value is measured at the greater of the appraised value or a predetermined floor. The amount that the Company could be required to pay to purchase the remaining 10% equity interest is not limited. As of March 30, 2024, the redemption value of $12.0 million exceeded the carrying value, resulting in an adjustment to additional paid in capital of $2.8 million. During the second quarter of fiscal 2024, the Company acquired the remaining 10% for $12.0 million. Vital River The Company held a 92% ownership interest in Vital River, a commercial provider of research models and related services in China as of December 31, 2022. The Company had the right to purchase, and the noncontrolling interest holders had the right to sell, the remaining 8% equity interest at a contractually defined redemption value, subject to a redemption floor. The amount that the Company could be required to pay to purchase the remaining 8% equity interest was not limited. During the fourth quarter of fiscal 2023, the Company acquired the remaining 8% and paid $4.8 million of the total $24.4 million due. The remaining purchase price payable was included in Accrued liabilities within the Company’s unaudited condensed consolidated balance sheet as of June 29, 2024 and December 30, 2023 and is expected to be paid during fiscal year 2024. Nonredeemable Noncontrolling Interest The Company has an investment in an entity whose financial results are consolidated in the Company’s unaudited condensed consolidated financial statements, as it has the ability to exercise control over this entity. The interest of the noncontrolling party in this entity has been recorded as nonredeemable noncontrolling interest within Equity in the accompanying unaudited condensed consolidated balance sheets. The activity within the nonredeemable noncontrolling interest was not material during the three and six months ended June 29, 2024 and July 1, 2023.

v3.24.2.u1

INCOME TAXES	6 Months Ended
	Jun. 29, 2024
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES The Company’s effective tax rates for the three months ended June 29, 2024 and July 1, 2023 were 21.2% and 22.7%, respectively. The decrease in the effective tax rate for the three months ended June 29, 2024 compared to the corresponding prior year period was primarily attributable to non-taxable remeasurement gains on previous equity investment in Noveprim during the three months ended June 29, 2024. The Company’s effective tax rates for the six months ended June 29, 2024 and July 1, 2023 were 22.8% and 21.7%, respectively. The increase in the effective tax rate for the six months ended June 29, 2024 compared to the same prior year is primarily attributable to decreased tax benefit from stock-based compensation deductions in the six months ended June 29, 2024. For the three months ended June 29, 2024, the Company’s unrecognized tax benefits increased by $0.6 million to $24.0 million, primarily due to increases in research and development tax credit reserves. For the three months ended June 29, 2024, the amount of unrecognized income tax benefits that would impact the effective tax rate increased by $0.4 million to $21.1 million for the same reasons discussed above. The accrued interest on unrecognized tax benefits was $1.6 million as of June 29, 2024. The Company estimates that it is reasonably possible that the unrecognized tax benefits will decrease by approximately $5 million over the next twelve-month period, primarily due to audit settlements and expiring statutes of limitations. The Company’s prepaid and accrued tax positions are as follows: June 29, 2024 December 30, 2023 Affected Line Item in the Unaudited Condensed Consolidated Balance Sheets (in thousands) Prepaid income tax $ 71,242  $ 59,715  Other current assets Accrued income taxes 35,126  38,819  Other current liabilities The Company conducts business in a number of tax jurisdictions. As a result, it is subject to tax audits on a regular basis including, but not limited to, such major jurisdictions as the U.S., the U.K., China, France, Germany, and Canada. With few exceptions, the Company is no longer subject to U.S. and international income tax examinations for years before 2020. The Company and certain of its subsidiaries have ongoing tax controversies in the U.S., Canada, and India. The Company does not anticipate resolution of these audits will have a material impact on its unaudited condensed consolidated financial statements.

v3.24.2.u1

RESTRUCTURING AND ASSET IMPAIRMENTS	6 Months Ended
	Jun. 29, 2024
Restructuring and Related Activities [Abstract]
RESTRUCTURING AND ASSET IMPAIRMENTS	RESTRUCTURING AND ASSET IMPAIRMENTS The Company has undertaken restructuring actions impacting the reportable segments at various locations across North America, Europe and Asia. This includes workforce right-sizing actions resulting in severance and transition costs; and costs related to the consolidation of facilities resulting in asset impairment and accelerated depreciation charges. Generally, these actions are considered to be short-term in nature in response to recent macroeconomic impacts on the Company. During fiscal year 2023, the Company began to take restructuring actions as a result of these emerging business trends. The Company incurred restructuring charges of $18.0 million and $35.0 million during the three and six months ended June 29, 2024, respectively and approximately $65 million throughout fiscal year 2023 through June 29, 2024. The following table presents restructuring costs by reportable segment: Three Months Ended Six Months Ended June 29, 2024 July 1, 2023 June 29, 2024 July 1, 2023 (in thousands) RMS $ 10,228  $ —  $ 17,615  $ —  DSA 3,766  —  10,257  (2) Manufacturing 2,657  2,699  4,288  6,187  Unallocated corporate 1,304  —  2,794  —  Total $ 17,955  $ 2,699  $ 34,954  $ 6,185  The following table presents restructuring costs as included within the Company’s unaudited condensed consolidated statements of income: June 29, 2024 July 1, 2023 Severance and Transition Costs Asset Impairments and Other Costs Total Severance and Transition Costs Asset Impairments and Other Costs Total (in thousands) Three Months Ended Cost of services provided (excluding amortization of intangible assets) $ 2,870  $ 1,926  $ 4,796  $ 2,361  $ —  $ 2,361  Cost of products sold (excluding amortization of intangible assets) 69  9,154  9,223  36  182  218  Selling, general and administrative 2,958  978  3,936  120  —  120  Total restructuring costs $ 5,897  $ 12,058  $ 17,955  $ 2,517  $ 182  $ 2,699  Six Months Ended Cost of services provided (excluding amortization of intangible assets) $ 7,680  $ 3,034  $ 10,714  $ 2,928  $ —  $ 2,928  Cost of products sold (excluding amortization of intangible assets) 747  10,484  11,231  54  2,746  2,800  Selling, general and administrative 6,507  6,502  13,009  449  8  457  Total restructuring costs $ 14,934  $ 20,020  $ 34,954  $ 3,431  $ 2,754  $ 6,185  Rollforward of Restructuring Activities The following table provides a rollforward for the Company’s accrued restructuring costs related to all restructuring activities: Severance and Transition Costs Asset Impairments Other Costs Total (in thousands) Six Months Ended June 29, 2024 Beginning balance $ 4,175  $ —  $ 875  $ 5,050  Expense 14,934  14,181  5,839  34,954  Payments / utilization (9,323) —  (5,067) (14,390) Other non-cash adjustments —  (14,181) (772) (14,953) Foreign currency adjustments (57) —  —  (57) Ending Balance $ 9,729  $ —  $ 875  $ 10,604  Six Months Ended July 1, 2023 Beginning balance $ 356  $ —  $ 944  $ 1,300  Expense 3,431  2,479  275  6,185  Payments / utilization (811) —  (303) (1,114) Other non-cash adjustments —  (2,479) —  (2,479) Foreign currency adjustments 9  —  —  9  Ending Balance $ 2,985  $ —  $ 916  $ 3,901  As of June 29, 2024 and December 30, 2023, $10.6 million and $5.1 million, respectively, of severance and other personnel related costs liabilities were included in accrued compensation and accrued liabilities within the Company’s unaudited condensed consolidated balance sheets.

v3.24.2.u1

COMMITMENTS AND CONTINGENCIES	6 Months Ended
	Jun. 29, 2024
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	COMMITMENTS AND CONTINGENCIES Litigation On February 16, 2023, the Company was informed by the U.S. Department of Justice (DOJ) that in conjunction with the U.S. Fish and Wildlife Service (USFWS), it had commenced an investigation into the Company’s conduct regarding several shipments of non-human primates from Cambodia. On February 17, 2023 the Company received a grand jury subpoena requesting certain documents related to such investigation. The Company is aware of a parallel civil investigation being undertaken by the DOJ and USFWS. The Company is cooperating with the DOJ and the USFWS and believes that the concerns raised with respect to the Company’s conduct are without merit. The Company maintains a global supplier onboarding and oversight program incorporating risk-based due diligence, auditing, and monitoring practices to help ensure the quality of our supplier relationships and compliance with applicable U.S. and international laws and regulations, and has operated under the belief that all shipments of non-human primates it received satisfied the material requirements, documentation and related processes and procedures of the Convention on International Trade in Endangered Species of Wild Fauna and Flora (CITES) documentation and related processes and procedures, which guides the release of each import by USFWS. Notwithstanding our efforts and good-faith belief, in connection with the civil investigation, the Company has voluntarily suspended future shipments of non-human primates from Cambodia to the United States until such time that the Company and USFWS can agree upon and implement additional procedures to reasonably ensure that non-human primates imported from Cambodia are purpose-bred. The Company continues to care for the Cambodia-sourced non-human primates from certain shipments in the United States. The carrying value of the inventory related to these shipments was approximately $27 million as of June 29, 2024, which reflects the value of the shipments in accordance with the Company’s inventory accounting policy. On May 16, 2023, the Company received an inquiry from the Enforcement Division of the U.S. Securities and Exchange Commission (SEC) requesting it to voluntarily provide information, subsequently augmented with a document subpoena and additional inquiries, primarily related to the sourcing of non-human primates and related disclosures, and the Company is cooperating with these requests. The Company is not able to predict what action, if any, might be taken in the future by the DOJ, USFWS, SEC or other governmental authorities as a result of the investigations. None of the DOJ, USFWS or SEC has provided the Company with any specific timeline or indication as to when these investigations or, specific to the DOJ and USFWS, discussions regarding future processes and procedures, will be concluded or resolved. The Company cannot predict the timing, outcome or possible impact of the investigations, including without limitation any potential fines, penalties or liabilities. A putative securities class action (Securities Class Action) was filed on May 19, 2023 against the Company and a number of its current/former officers in the United States District Court for the District of Massachusetts. On August 31, 2023, the court appointed the State Teachers Retirement System of Ohio as lead plaintiff. An amended complaint was filed on November 14, 2023 that, among other things, included only James Foster, the Chief Executive Officer and David R. Smith, the former Chief Financial Officer as defendants along with the Company. The amended complaint asserts claims under §§ 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") on behalf of a putative class of purchasers of Company securities from May 5, 2020 through February 21, 2023, alleging that certain of the Company’s disclosures about its practices with respect to the importation of non-human primates made during the putative class period were materially false or misleading. On July 1, 2024, the court dismissed the complaint, denied the plaintiff’s informal request for leave to amend, and entered judgment for defendants. On July 30, 2024 the plaintiff filed a notice of appeal. While the Company cannot predict the final outcome of this matter, it believes the class action to be without merit and plans to vigorously defend against it. The Company cannot reasonably estimate the maximum potential exposure or the range of possible loss in association with this matter. On November 8, 2023, a stockholder filed a derivative lawsuit in the U.S. District Court of the District of Delaware asserting claims on the Company’s behalf against the members of the Company’s Board of Directors and certain of the Company’s current/former officers (James Foster, the Chief Executive Officer; David R. Smith, the former Chief Financial Officer; and Flavia Pease, the current Chief Financial Officer). The complaint alleges that the defendants breached their fiduciary duties to the Company and its stockholders because certain of the Company’s disclosures about its practices with respect to the importation of non-human primates were materially false or misleading. The complaint also alleges that the defendants breached their fiduciary duties by causing the Company to fail to maintain adequate internal controls over securities disclosure and compliance with applicable law and by failing to comply with the company’s Code of Business Conduct and Ethics. The lawsuit is currently stayed by agreement of the parties pending further developments in the Securities Class Action pending in the United States District Court for the District of Massachusetts. On August 2, 2024, a different stockholder filed a lawsuit in the U.S. District Court of Delaware asserting similar derivative claims on the Company’s behalf against members of the Company’s current and former Board of Directors and the same current/former officers based on similar allegations of purportedly misleading disclosures and non-compliance with legal rules and ethics standards in respect of the importation of non-human primates, as well as insider-trading claims against certain of the defendants. While the Company cannot predict the outcome of these matters, it believes the derivative lawsuits to be without merit and plans to vigorously defend against them. The Company cannot reasonably estimate the maximum potential exposure or the range of possible loss in association with these matters. Aside from the matters above, the Company believes there are no other matters pending against the Company that could have a material impact on the Company’s business, financial condition, or results of operations.

v3.24.2.u1

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 29, 2024	Jul. 01, 2023	Jun. 29, 2024	Jul. 01, 2023
Pay vs Performance Disclosure
Net income available to Charles River Laboratories International, Inc.	$ 94,081	$ 97,020	$ 167,041	$ 200,151

v3.24.2.u1

Insider Trading Arrangements	3 Months Ended
	Jun. 29, 2024
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

v3.24.2.u1

BASIS OF PRESENTATION (Policies)	6 Months Ended
	Jun. 29, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	The accompanying condensed consolidated financial statements are unaudited and have been prepared by Charles River Laboratories International, Inc. (the Company) in accordance with accounting principles generally accepted in the United States (U.S. GAAP) and pursuant to the rules and regulations of the Securities and Exchange Commission (SEC). The year-end condensed consolidated balance sheet data was derived from the Company’s audited consolidated financial statements, but does not include all disclosures required by U.S. GAAP. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K for fiscal year 2023 as filed with the SEC on February 14, 2024. Certain reclassifications of prior year amounts have been made to conform to the current year presentation. The unaudited condensed consolidated financial statements, in the opinion of management, reflect all normal and recurring adjustments necessary for a fair statement of the Company’s financial position and results of operations.
Use of Estimates	Use of Estimates The preparation of unaudited condensed consolidated financial statements in accordance with U.S. GAAP requires that the Company make estimates and judgments that may affect the reported amounts of assets, liabilities, revenues, expenses and related disclosure of contingent assets and liabilities. On an on-going basis, the Company evaluates its estimates, judgments, and methodologies. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ from these estimates under different assumptions or conditions. Changes in estimates are reflected in reported results in the period in which they become known.
Newly Issued Accounting Pronouncements	Newly Issued Accounting Pronouncements In November 2023, the FASB issued ASU 2023-07, “Improvements to Reportable Segment Disclosures (Topic 280)”. ASU 2023-07 modifies reportable segment disclosure requirements, primarily through enhanced disclosures about segment expenses categorized as significant or regularly provided to the Chief Operating Decision Maker (CODM). In addition, the amendments enhance interim disclosure requirements, clarify circumstances in which an entity can disclose multiple segment measures of profit or loss, and contain other disclosure requirements. The purpose of the amendments is to enable investors to better understand an entity’s overall performance and assess potential future cash flows. This ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted and the amendments in this update are required to be applied on a retrospective basis. The Company is currently evaluating the impact this new standard will have on the related disclosures in the annual consolidated financial statements, but does not believe there will be a material impact. In December 2023, the FASB issued ASU 2023-09, “Improvements to Income Tax Disclosures (Topic 740)”. ASU 2023-09 requires enhanced disclosures on income taxes paid, adds disaggregation of continuing operations before income taxes between foreign and domestic earnings and defines specific categories for the reconciliation of jurisdictional tax rate to effective tax rate. This ASU is effective for fiscal years beginning after December 15, 2024, and can be applied on a prospective basis. The Company is currently evaluating the impact this new standard will have on the related disclosures on the consolidated financial statements.
Consolidation	Consolidation The Company’s unaudited condensed consolidated financial statements reflect its financial statements and those of its subsidiaries in which the Company holds a controlling financial interest. For consolidated entities in which the Company owns or is exposed to less than 100% of the economics, the Company records net income (loss) attributable to noncontrolling interests in its unaudited condensed consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Redeemable noncontrolling interests, where the noncontrolling interest holders have the ability to require the Company to purchase the remaining interests, are classified in the mezzanine section of the unaudited condensed consolidated balance sheets, which is presented above the equity section and below liabilities. Intercompany balances and transactions are eliminated in consolidation. The Company’s fiscal year is typically based on 52-weeks, with each quarter composed of 13 weeks ending on the last Saturday on, or closest to, March 31, June 30, September 30, and December 31. A 53rd week in the fourth quarter of the fiscal year is occasionally necessary to align with a December 31 calendar year-end.
Segment Reporting	Segment Reporting The Company reports its results in three reportable segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The Company’s RMS reportable segment includes the Research Models, Research Model Services, and Cell Solutions businesses. Research Models includes the commercial production and sale of small research models, as well as the supply of large research models. Research Model Services includes: Insourcing Solutions (IS), which provides colony management of clients’ research operations (including recruitment, training, staffing, and management services) within the clients’ facilities and utilizing the Charles River Accelerator and Development Lab (CRADL™) offering, which provides vivarium space to clients, Genetically Engineered Models and Services (GEMS), which performs contract breeding and other services associated with genetically engineered models, and Research Animal Diagnostic Services (RADS), which provides health monitoring and diagnostics services related to research models; and Cell Solutions, which supplies controlled, consistent, customized primary cells and blood components derived from normal and mobilized peripheral blood and bone marrow. The Company’s DSA reportable segment includes two businesses: Discovery Services and Safety Assessment. The Company provides regulated and non-regulated DSA services to support the research, development, and regulatory-required safety testing of potential new drugs, including therapeutic discovery and optimization plus in vitro and in vivo studies, laboratory support services, and strategic non-clinical consulting and program management to support product development. The Company’s Manufacturing reportable segment includes Microbial Solutions, which provides in vitro (non-animal) lot-release testing products, microbial detection products, and species identification services and Biologics Solutions (Biologics), which performs specialized testing of biologics (Biologics Testing Solutions) as well as contract development and manufacturing products and services (CDMO).

v3.24.2.u1

ACQUISITIONS AND DIVESTITURES (Tables)	6 Months Ended
	Jun. 29, 2024
Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]
Schedule of Purchase Price Allocation and Transaction and Integration Costs	The purchase price allocation was as follows: Noveprim Group(1) SAMDI Tech, Inc. November 30, 2023 January 27, 2023 (in thousands) Trade receivables $ 1,308  $ 513  Inventories 66,500  —  Other current assets (excluding cash) 3,261  75  Property, plant and equipment 36,154  593  Operating lease right-of-use asset, net 104  —  Goodwill (2) 190,024  37,129  Definite-lived intangible assets 9,500  33,070  Other long-term assets (3) 167,907  6  Deferred revenue —  (43) Other current liabilities (16,268) (351) Operating lease right-of-use liabilities (Long-term) (97) —  Deferred tax liabilities (12,984) (8,191) Other long-term liabilities (7,579) —  Redeemable noncontrolling interest (4) (45,426) —  Total purchase price allocation $ 392,404  $ 62,801  (1) Purchase price allocation is preliminary and subject to change as additional information becomes available concerning the fair value and tax basis of the assets acquired and liabilities assumed, including certain contracts, obligations, and finalization of any working capital adjustments. Any additional adjustments to the purchase price allocation will be made as soon as practicable but no later than one year from the date of acquisition. (2) The goodwill resulting from these transactions is primarily attributable to the potential growth of the Company’s segments from new customers introduced to the acquired businesses or synergies to be realized from acquiring an internal supplier servicing the DSA business and the assembled workforce of the acquirees, thus is not deductible for tax purposes. (3) Other long-term assets acquired from the Noveprim acquisition include $167.8 million of biological assets, which will be amortized over an estimated eight-year useful life. (4) Refer to Note 12. Equity and Noncontrolling Interests for further a description of the 10% noncontrolling interest fair value.
Schedule of Definite-Lived Intangible Assets Acquired as Part of Business Combination	The definite-lived intangible assets acquired were as follows: Noveprim Group SAMDI Tech, Inc. Definite-Lived Intangible Assets (in thousands) Client relationships $ —  $ 23,400  Other intangible assets 9,500  9,670  Total definite-lived intangible assets $ 9,500  $ 33,070  Weighted Average Amortization Life (in years) Client relationships —  15 Other intangible assets 7 7 Total definite-lived intangible assets 7 12

v3.24.2.u1

REVENUE FROM CONTRACTS WITH CUSTOMERS (Tables)	6 Months Ended
	Jun. 29, 2024
Revenue from Contract with Customer [Abstract]
Schedule of Disaggregation of Revenue	The following table disaggregates the Company’s revenue by major business line and timing of transfer of products or services: Three Months Ended Six Months Ended June 29, 2024 July 1, 2023 June 29, 2024 July 1, 2023 (in thousands) Timing of Revenue Recognition: RMS Services and products transferred over time $ 95,299  $ 94,458  $ 192,348  $ 188,097  Services and products transferred at a point in time 111,090  115,490  234,948  221,617  Total RMS revenue 206,389  209,948  427,296  409,714  DSA Services and products transferred over time 626,785  662,653  1,230,910  1,324,489  Services and products transferred at a point in time 634  804  1,961  1,321  Total DSA revenue 627,419  663,457  1,232,871  1,325,810  Manufacturing Services and products transferred over time 104,481  100,460  204,539  186,546  Services and products transferred at a point in time 87,828  86,072  172,971  167,240  Total Manufacturing revenue 192,309  186,532  377,510  353,786  Total revenue $ 1,026,117  $ 1,059,937  $ 2,037,677  $ 2,089,310  Revenue by geographic area is as follows: U.S. Europe Canada Asia Pacific Other Consolidated (in thousands) Three Months Ended: June 29, 2024 $ 571,427  $ 271,377  $ 125,244  $ 50,387  $ 7,682  $ 1,026,117  July 1, 2023 606,775  272,976  117,647  59,864  2,675  1,059,937  Six Months Ended: June 29, 2024 $ 1,133,744  $ 547,696  $ 235,645  $ 96,159  $ 24,433  $ 2,037,677  July 1, 2023 1,212,216  540,679  228,253  102,677  5,485  2,089,310
Schedule of Client Receivables, Contract Assets and Contract Liabilities	The following table provides information about client receivables, contract assets, and contract liabilities from contracts with customers: June 29, 2024 December 30, 2023 (in thousands) Assets from contracts with customers Client receivables $ 568,283  $ 578,077  Unbilled revenue 218,889  228,020  Total 787,172  806,097  Less: Allowance for credit losses (24,951) (25,722) Trade receivables and contract assets, net $ 762,221  $ 780,375  Liabilities from contracts with customers Current deferred revenue $ 247,177  $ 241,820  Long-term deferred revenue (included in Other long-term liabilities) 29,139  30,919  Customer contract deposits (included in Other current liabilities) 92,032  85,554  The associated revenue is recognized on a straight-line basis over the term of the lease, which is generally less than one year. Three Months Ended Six Months Ended June 29, 2024 July 1, 2023 June 29, 2024 July 1, 2023 (in thousands) Affected Line Item in the Unaudited Condensed Consolidated Statements of Income Lease revenue $ 16,716  $ 23,891  $ 37,690  $ 47,981  Service revenue
Schedule of Allowance for Credit Losses	The following is a summary of the activity of the Company’s allowance for credit losses: Six Months Ended June 29, 2024 July 1, 2023 (in thousands) Beginning balance $ 25,722  $ 11,278  Provisions 4,719  9,849  Reductions (5,490) (3,087) Ending balance $ 24,951  $ 18,040

v3.24.2.u1

SEGMENT AND GEOGRAPHIC INFORMATION (Tables)	6 Months Ended
	Jun. 29, 2024
Segment Reporting [Abstract]
Schedule of Revenue and Other Financial Information by Business Segment	The following table presents the results of operations by reportable segment: Three Months Ended Six Months Ended June 29, 2024 July 1, 2023 June 29, 2024 July 1, 2023 (in thousands) RMS     Revenue $ 206,389  $ 209,948  $ 427,296  $ 409,714  Cost of revenue (excluding amortization of intangible assets) 142,942  127,888  283,867  254,692  Selling, general and administrative 27,597  27,653  58,490  54,711  Amortization of intangible assets 5,902  5,489  11,842  10,984  Operating income $ 29,948  $ 48,918  $ 73,097  $ 89,327  DSA Revenue $ 627,419  $ 663,457  $ 1,232,871  $ 1,325,810  Cost of revenue (excluding amortization of intangible assets) 418,964  420,551  836,876  832,074  Selling, general and administrative 54,479  63,709  111,338  125,707  Amortization of intangible assets 15,600  17,659  31,442  35,060  Operating income $ 138,376  $ 161,538  $ 253,215  $ 332,969  Manufacturing Revenue $ 192,309  $ 186,532  $ 377,510  $ 353,786  Cost of revenue (excluding amortization of intangible assets) 110,498  112,522  218,378  225,914  Selling, general and administrative 33,813  38,481  66,660  78,218  Amortization of intangible assets 10,768  11,126  21,561  23,145  Operating income $ 37,230  $ 24,403  $ 70,911  $ 26,509  Unallocated Corporate Selling, general and administrative $ 53,902  $ 69,914  $ 119,594  $ 115,968  Operating income (1) $ (53,902) $ (69,914) $ (119,594) $ (115,968) Consolidated Revenue $ 1,026,117  $ 1,059,937  $ 2,037,677  $ 2,089,310  Cost of revenue (excluding amortization of intangible assets) 672,404  660,960  1,339,121  1,312,679  Selling, general and administrative 169,791  199,758  356,082  374,604  Amortization of intangible assets 32,270  34,274  64,845  69,190  Operating income $ 151,652  $ 164,945  $ 277,629  $ 332,837  (1) Operating income for unallocated corporate consists of costs associated with departments such as senior executives, corporate accounting, legal, tax, human resources, treasury, and investor relations. Capital expenditures and depreciation and amortization (related to both intangible assets and certain assets acquired in business combinations) by reportable segment are as follows: RMS DSA Manufacturing Unallocated Corporate Consolidated (in thousands) Capital Expenditures Three Months Ended: June 29, 2024 $ 9,313  $ 19,444  $ 10,583  $ 146  $ 39,486  July 1, 2023 7,493  48,326  10,862  702  67,383  Six Months Ended: June 29, 2024 $ 29,357  $ 68,403  $ 19,445  $ 1,425  $ 118,630  July 1, 2023 26,577  113,510  32,600  1,571  174,258  Depreciation and amortization Three Months Ended: June 29, 2024 $ 16,538  $ 47,729  $ 20,073  $ 1,742  $ 86,082  July 1, 2023 13,949  43,124  19,523  1,075  77,671  Six Months Ended: June 29, 2024 $ 34,661  $ 93,518  $ 39,878  $ 3,382  $ 171,439  July 1, 2023 27,438  85,574  39,607  2,121  154,740
Schedule of Revenue by Geographic Area	The following table disaggregates the Company’s revenue by major business line and timing of transfer of products or services: Three Months Ended Six Months Ended June 29, 2024 July 1, 2023 June 29, 2024 July 1, 2023 (in thousands) Timing of Revenue Recognition: RMS Services and products transferred over time $ 95,299  $ 94,458  $ 192,348  $ 188,097  Services and products transferred at a point in time 111,090  115,490  234,948  221,617  Total RMS revenue 206,389  209,948  427,296  409,714  DSA Services and products transferred over time 626,785  662,653  1,230,910  1,324,489  Services and products transferred at a point in time 634  804  1,961  1,321  Total DSA revenue 627,419  663,457  1,232,871  1,325,810  Manufacturing Services and products transferred over time 104,481  100,460  204,539  186,546  Services and products transferred at a point in time 87,828  86,072  172,971  167,240  Total Manufacturing revenue 192,309  186,532  377,510  353,786  Total revenue $ 1,026,117  $ 1,059,937  $ 2,037,677  $ 2,089,310  Revenue by geographic area is as follows: U.S. Europe Canada Asia Pacific Other Consolidated (in thousands) Three Months Ended: June 29, 2024 $ 571,427  $ 271,377  $ 125,244  $ 50,387  $ 7,682  $ 1,026,117  July 1, 2023 606,775  272,976  117,647  59,864  2,675  1,059,937  Six Months Ended: June 29, 2024 $ 1,133,744  $ 547,696  $ 235,645  $ 96,159  $ 24,433  $ 2,037,677  July 1, 2023 1,212,216  540,679  228,253  102,677  5,485  2,089,310
Schedule of Long-Lived Assets by Geographic Area	Long-lived assets by geographic area are as follows: U.S. Europe Canada Asia Pacific Other Consolidated (in thousands) Long-lived assets June 29, 2024 $ 950,254  $ 405,429  $ 153,945  $ 68,868  $ 35,399  $ 1,613,895  December 30, 2023 964,176  407,375  157,483  74,605  36,102  1,639,741

v3.24.2.u1

SUPPLEMENTAL CASH FLOW INFORMATION (Tables)	6 Months Ended
	Jun. 29, 2024
Supplemental Cash Flow Information [Abstract]
Schedule of Supplemental Cash Flow Information	Six Months Ended June 29, 2024 July 1, 2023 (in thousands) Cash paid for income taxes $ 71,722  $ 61,816  Cash paid for interest 65,630  66,563  Non-cash investing activities: Purchases of Property, plant and equipment included in Accounts payable and Accrued liabilities $ 25,278  $ 47,850  Assets acquired under finance leases 3,159  154  Cash, cash equivalents and restricted cash is included in the accompanying unaudited balance sheet as follows: June 29, 2024 December 30, 2023 (in thousands) Supplemental cash flow information: Cash and cash equivalents $ 179,213  $ 276,771  Restricted cash included in Other current assets 325  5,803  Restricted cash included in Other assets 1,466  1,906  Cash, cash equivalents, and restricted cash, end of period $ 181,004  $ 284,480

v3.24.2.u1

INVENTORY (Tables)	6 Months Ended
	Jun. 29, 2024
Inventory Disclosure [Abstract]
Schedule of Composition of Inventories	The composition of inventories is as follows: June 29, 2024 December 30, 2023 (in thousands) Raw materials and supplies $ 43,238  $ 42,296  Work in process 57,923  59,727  Finished products 247,950  278,236  Inventories $ 349,111  $ 380,259

v3.24.2.u1

PROPERTY, PLANT AND EQUIPMENT, NET (Tables)	6 Months Ended
	Jun. 29, 2024
Property, Plant and Equipment [Abstract]
Schedule of Composition of Property, Plant and Equipment, Net	The composition of property, plant and equipment, net is as follows: June 29, 2024 December 30, 2023 (in thousands) Land $ 78,812  $ 79,546  Buildings (1) 1,061,408  1,053,915  Machinery and equipment (1) 1,007,210  984,867  Leasehold improvements 381,879  366,556  Furniture and fixtures 32,060  31,284  Computer hardware and software (1) 259,889  254,413  Vehicles (1) 7,149  6,746  Construction in progress 182,823  197,723  Total 3,011,230  2,975,050  Less: Accumulated depreciation (1,397,335) (1,335,309) Property, plant and equipment, net $ 1,613,895  $ 1,639,741  (1) These balances include assets under finance leases.

v3.24.2.u1

VENTURE CAPITAL AND STRATEGIC EQUITY INVESTMENTS - (Tables)	6 Months Ended
	Jun. 29, 2024
Equity Method Investments and Joint Ventures [Abstract]
Schedule of Equity Method Investments	Venture capital investments are summarized below: Six Months Ended June 29, 2024 July 1, 2023 (in thousands) Beginning balance $ 121,158  $ 129,012  Capital contributions 6,479  8,702  Distributions (16,100) (9,679) Gains (losses) 1,789  (8,429) Foreign currency translation (249) 466  Ending balance $ 113,077  $ 120,072  The Company also invests, with minority positions, directly in equity of predominantly privately held companies. Strategic investments are summarized below: Six Months Ended June 29, 2024 July 1, 2023 (in thousands) Beginning balance $ 122,653  $ 182,590  Purchase of investments 2,140  13,710  Distributions —  (4,146) Gain (loss) (5,265) 3,253  Reduction for acquisition of entity (1) —  (12,635) Foreign currency translation (746) (2,563) Ending balance $ 118,782  $ 180,209  (1) Refer to Note 2. Acquisitions for further discussion on the acquisition of SAMDI.

v3.24.2.u1

FAIR VALUE (Tables)	6 Months Ended
	Jun. 29, 2024
Fair Value Disclosures [Abstract]
Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis	Assets and liabilities measured at fair value on a recurring basis are summarized below:   June 29, 2024 Level 1 Level 2 Level 3 Total Current assets measured at fair value: (in thousands) Cash equivalents $ —  $ 7,257  $ —  $ 7,257  Term deposit —  26,983  —  26,983  Other assets: Life insurance policies —  45,210  —  45,210  Interest rate swap —  1,338  —  1,338  Total assets measured at fair value $ —  $ 80,788  $ —  $ 80,788  Other long-term liabilities measured at fair value: Contingent consideration $ —  $ —  $ 38,335  $ 38,335  Total liabilities measured at fair value $ —  $ —  $ 38,335  $ 38,335    December 30, 2023 Level 1 Level 2 Level 3 Total Current assets measured at fair value: (in thousands) Cash equivalents $ —  $ 29  $ —  $ 29  Other assets: Life insurance policies —  40,912  —  40,912  Interest rate swap —  966  —  966  Total assets measured at fair value $ —  $ 41,907  $ —  $ 41,907  Other long-term liabilities measured at fair value Contingent consideration $ —  $ —  $ 33,265  $ 33,265  Total liabilities measured at fair value $ —  $ —  $ 33,265  $ 33,265  The book value and fair value of the Company’s Senior Notes is summarized below: June 29, 2024 December 30, 2023 Book Value Fair Value Book Value Fair Value (in thousands) 4.25% Senior Notes due 2028 $ 500,000  $ 468,750  $ 500,000  $ 478,100  3.75% Senior Notes due 2029 500,000  453,750  500,000  458,100  4.00% Senior Notes due 2031 500,000  445,000  500,000  449,350
Schedule of Rollforward of Contingent Consideration Related to Previous Acquisitions	The following table provides a rollforward of the contingent consideration related to the Company’s acquisitions. Six Months Ended June 29, 2024 July 1, 2023 (in thousands) Beginning balance $ 33,265  $ 13,431  Payments —  (15,130) Total gains or losses (realized/unrealized): Adjustment of previously recorded contingent liability 5,070  1,810  Foreign currency translation —  (111) Ending balance $ 38,335  $ —

v3.24.2.u1

GOODWILL AND INTANGIBLE ASSETS (Tables)	6 Months Ended
	Jun. 29, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Goodwill	The following table provides a rollforward of the Company’s goodwill: RMS DSA (1) Manufacturing Total (in thousands) December 30, 2023 $ 497,474  $ 1,662,434  $ 935,137  $ 3,095,045  Acquisitions —  17,675  —  17,675  Foreign exchange (536) (29,251) (3,240) (33,027) June 29, 2024 $ 496,938  $ 1,650,858  $ 931,897  $ 3,079,693  (1) DSA includes accumulated impairment losses of $1 billion, which were recognized in fiscal years 2008 and 2010.
Schedule of Intangible Assets	The following table displays intangible assets, net by major class:   June 29, 2024 December 30, 2023 Gross Accumulated Amortization Net Gross Accumulated Amortization Net (in thousands) Client relationships $ 1,518,194  $ (766,261) $ 751,933  $ 1,528,780  $ (721,322) $ 807,458  Technology 140,737  (114,410) 26,327  142,190  (111,764) 30,426  Trademarks and trade names 11,849  (5,098) 6,751  11,878  (4,568) 7,310  Backlog 3,100  (2,792) 308  3,100  (2,177) 923  Other 42,866  (28,056) 14,810  43,611  (25,677) 17,934  Intangible assets $ 1,716,746  $ (916,617) $ 800,129  $ 1,729,559  $ (865,508) $ 864,051

v3.24.2.u1

DEBT AND OTHER FINANCING ARRANGEMENTS (Tables)	6 Months Ended
	Jun. 29, 2024
Debt Disclosure [Abstract]
Schedule of Long-term Debt and Finance Lease Obligations	Long-term debt, net and finance leases consists of the following: June 29, 2024 December 30, 2023 (in thousands) Revolving facility $ 879,498  $ 1,129,243  4.25% Senior Notes due 2028 500,000  500,000  3.75% Senior Notes due 2029 500,000  500,000  4.00% Senior Notes due 2031 500,000  500,000  Other debt 16,125  9,575  Finance leases 29,637  28,550  Total debt and finance leases 2,425,260  2,667,368  Less: Current portion of long-term debt 435  3,172  Current portion of finance leases 2,778  2,398  Current portion of long-term debt and finance leases 3,213  5,570  Long-term debt and finance leases 2,422,047  2,661,798  Debt discount and debt issuance costs (12,667) (14,651) Long-term debt, net and finance leases $ 2,409,380  $ 2,647,147

v3.24.2.u1

EQUITY AND NONCONTROLLING INTERESTS (Tables)	6 Months Ended
	Jun. 29, 2024
Equity [Abstract]
Schedule of Reconciliation of the Numerator and Denominator in the Computations of the Basic and Diluted Earnings Per Share	The following table reconciles the numerator and denominator in the computations of basic and diluted earnings per share: Three Months Ended Six Months Ended June 29, 2024 July 1, 2023 June 29, 2024 July 1, 2023 (in thousands) Numerator:     Net income $ 94,261  $ 99,443  $ 168,743  $ 203,397  Less: Net income attributable to noncontrolling interests 180  2,423  1,702  3,246  Net income available to Charles River Laboratories International, Inc. 94,081  97,020  167,041  200,151  Calculation of net income per share attributable to common shareholders of Charles River Laboratories International, Inc. Net income available to Charles River Laboratories International, Inc. $ 94,081  $ 97,020  $ 167,041  $ 200,151  Less: Adjustment of redeemable noncontrolling interest (1) 301  —  702  —  Less: Incremental dividends attributable to noncontrolling interest holders (2) 3,792  —  9,022  —  Net income available to Charles River Laboratories International, Inc. common shareholders $ 89,988  $ 97,020  $ 157,317  $ 200,151  Denominator:     Weighted-average shares outstanding - Basic 51,551  51,216  51,494  51,157  Effect of dilutive securities: Stock options, restricted stock units and performance share units 295  251  316  225  Weighted-average shares outstanding - Diluted 51,846  51,467  51,810  51,382  Anti-dilutive common stock equivalents (3) 506  594  482  589  (1) Represents adjustments of redeemable noncontrolling interest that impact retained earnings. (2) Represents incremental undeclared dividends attributable to Noveprim noncontrolling interest holders who are entitled to preferential dividends for fiscal year 2024. (3) These common stock equivalents were outstanding for the periods presented, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.
Schedule of Accumulated Other Comprehensive Income (Loss)	Changes to each component of accumulated other comprehensive income (loss), net of income taxes, are as follows: Foreign Currency Translation Adjustment and Other Pension and Other Post-Retirement Benefit Plans Net Unrealized (Loss) Gain on Cash Flow Hedge Total (in thousands) December 30, 2023 $ (149,999) $ (47,167) $ 739  $ (196,427) Other comprehensive income (loss) before reclassifications (81,840) 686  372  (80,782) Net current period other comprehensive income (loss) (81,840) 686  372  (80,782) Income tax expense (benefit) (7,759) 170  89  (7,500) June 29, 2024 $ (224,080) $ (46,651) $ 1,022  $ (269,709)

v3.24.2.u1

INCOME TAXES (Tables)	6 Months Ended
	Jun. 29, 2024
Income Tax Disclosure [Abstract]
Schedule of Prepaid and Accrued Tax Positions	The Company’s prepaid and accrued tax positions are as follows: June 29, 2024 December 30, 2023 Affected Line Item in the Unaudited Condensed Consolidated Balance Sheets (in thousands) Prepaid income tax $ 71,242  $ 59,715  Other current assets Accrued income taxes 35,126  38,819  Other current liabilities

v3.24.2.u1

RESTRUCTURING AND ASSET IMPAIRMENTS (Tables)	6 Months Ended
	Jun. 29, 2024
Restructuring and Related Activities [Abstract]
Schedule of Restructuring Costs	The following table presents restructuring costs by reportable segment: Three Months Ended Six Months Ended June 29, 2024 July 1, 2023 June 29, 2024 July 1, 2023 (in thousands) RMS $ 10,228  $ —  $ 17,615  $ —  DSA 3,766  —  10,257  (2) Manufacturing 2,657  2,699  4,288  6,187  Unallocated corporate 1,304  —  2,794  —  Total $ 17,955  $ 2,699  $ 34,954  $ 6,185  The following table presents restructuring costs as included within the Company’s unaudited condensed consolidated statements of income: June 29, 2024 July 1, 2023 Severance and Transition Costs Asset Impairments and Other Costs Total Severance and Transition Costs Asset Impairments and Other Costs Total (in thousands) Three Months Ended Cost of services provided (excluding amortization of intangible assets) $ 2,870  $ 1,926  $ 4,796  $ 2,361  $ —  $ 2,361  Cost of products sold (excluding amortization of intangible assets) 69  9,154  9,223  36  182  218  Selling, general and administrative 2,958  978  3,936  120  —  120  Total restructuring costs $ 5,897  $ 12,058  $ 17,955  $ 2,517  $ 182  $ 2,699  Six Months Ended Cost of services provided (excluding amortization of intangible assets) $ 7,680  $ 3,034  $ 10,714  $ 2,928  $ —  $ 2,928  Cost of products sold (excluding amortization of intangible assets) 747  10,484  11,231  54  2,746  2,800  Selling, general and administrative 6,507  6,502  13,009  449  8  457  Total restructuring costs $ 14,934  $ 20,020  $ 34,954  $ 3,431  $ 2,754  $ 6,185
Schedule of Rollforward of Company's Severance and Retention Costs Liability	The following table provides a rollforward for the Company’s accrued restructuring costs related to all restructuring activities: Severance and Transition Costs Asset Impairments Other Costs Total (in thousands) Six Months Ended June 29, 2024 Beginning balance $ 4,175  $ —  $ 875  $ 5,050  Expense 14,934  14,181  5,839  34,954  Payments / utilization (9,323) —  (5,067) (14,390) Other non-cash adjustments —  (14,181) (772) (14,953) Foreign currency adjustments (57) —  —  (57) Ending Balance $ 9,729  $ —  $ 875  $ 10,604  Six Months Ended July 1, 2023 Beginning balance $ 356  $ —  $ 944  $ 1,300  Expense 3,431  2,479  275  6,185  Payments / utilization (811) —  (303) (1,114) Other non-cash adjustments —  (2,479) —  (2,479) Foreign currency adjustments 9  —  —  9  Ending Balance $ 2,985  $ —  $ 916  $ 3,901

v3.24.2.u1

BASIS OF PRESENTATION (Details)	6 Months Ended
	Jun. 29, 2024 subsegment segment
Number of reportable segments | segment	3
Discover and Safety Assessment Segment
Number of businesses in reportable segment | subsegment	2

v3.24.2.u1

ACQUISITIONS AND DIVESTITURES - Narrative (Details) - USD ($)		3 Months Ended		6 Months Ended		12 Months Ended	23 Months Ended
	Jan. 27, 2023	Jun. 29, 2024	Jul. 01, 2023	Jun. 29, 2024	Jul. 01, 2023	Dec. 31, 2022	Nov. 30, 2023
Business Acquisition [Line Items]
Cash portion of consideration transferred				$ 5,479,000	$ 50,166,000
Noveprim Group
Business Acquisition [Line Items]
Percentage of voting interests acquired							41.00%
Equity interest acquired							90.00%
Business combination, equity stake percentage						49.00%
Purchases of additional equity interests, net						$ 90,000,000.0
Contingent liability						$ 5,000,000
Purchase price							$ 392,400,000
Additional cash paid							144,600,000
Business combination, consideration transferred, other							209,500,000
Gain in equity equal to the excess fair value of additional equity interest purchased		$ 9,800,000					113,000,000.0
Contingent consideration							33,300,000
Business combination deferred purchase price							12,000,000.0
Adjustments for working capital/debt		7,000,000.0		7,000,000.0			13,800,000
Goodwill, purchase accounting adjustments		17,600,000
Consideration contingent upon future performance							$ 55,000,000.0
Business combination, remaining equity to purchase							10.00%
Call option term, period after sixth anniversary							1 month
Put option term, period after first anniversary							12 months
Transaction and integration costs		700,000	$ 1,400,000	900,000	2,200,000
Noveprim Group | Minimum
Business Acquisition [Line Items]
Business combination, redemption price							$ 47,000,000.0
Noveprim Group | Maximum
Business Acquisition [Line Items]
Business combination, redemption price							$ 54,000,000.0
SAMDI Tech, Inc.
Business Acquisition [Line Items]
Business combination, equity stake percentage	20.00%
Transaction and integration costs		$ 0	$ 300,000	$ 0	$ 300,000
Cash portion of consideration transferred	$ 62,800,000
Cash acquired	400,000
Value of previously owned interest in acquiree	$ 12,600,000

v3.24.2.u1

ACQUISITIONS AND DIVESTITURES - Schedule of Purchase Price Allocation (Details) - USD ($) $ in Thousands	Jun. 29, 2024	Dec. 30, 2023	Nov. 30, 2023	Jan. 27, 2023
Business Acquisition [Line Items]
Goodwill	$ 3,079,693	$ 3,095,045
Noveprim Group
Business Acquisition [Line Items]
Trade receivables			$ 1,308
Inventories			66,500
Other current assets (excluding cash)			3,261
Property, plant and equipment			36,154
Operating lease right-of-use asset, net			104
Goodwill			190,024
Definite-lived intangible assets			9,500
Other long-term assets			167,907
Deferred revenue			0
Other current liabilities			(16,268)
Operating lease right-of-use liabilities (Long-term)			(97)
Deferred tax liabilities			(12,984)
Other long-term liabilities			(7,579)
Redeemable noncontrolling interest			(45,426)
Total purchase price allocation			392,404
Biological assets			$ 167,800
Biological assets, useful life			8 years
Business combination, remaining equity to purchase			10.00%
SAMDI Tech, Inc.
Business Acquisition [Line Items]
Trade receivables				$ 513
Inventories				0
Other current assets (excluding cash)				75
Property, plant and equipment				593
Operating lease right-of-use asset, net				0
Goodwill				37,129
Definite-lived intangible assets				33,070
Other long-term assets				6
Deferred revenue				(43)
Other current liabilities				(351)
Operating lease right-of-use liabilities (Long-term)				0
Deferred tax liabilities				(8,191)
Other long-term liabilities				0
Redeemable noncontrolling interest				0
Total purchase price allocation				$ 62,801

v3.24.2.u1

ACQUISITIONS AND DIVESTITURES - Schedule of Definite-Lived Intangible Assets (Details) - USD ($) $ in Thousands	Nov. 30, 2023	Jan. 27, 2023
Noveprim Group
Business Acquisition [Line Items]
Definite-Lived Intangible Assets	$ 9,500
Weighted Average Amortization Life	7 years
SAMDI Tech, Inc.
Business Acquisition [Line Items]
Definite-Lived Intangible Assets		$ 33,070
Weighted Average Amortization Life		12 years
Client relationships | Noveprim Group
Business Acquisition [Line Items]
Definite-Lived Intangible Assets	$ 0
Weighted Average Amortization Life	0 years
Client relationships | SAMDI Tech, Inc.
Business Acquisition [Line Items]
Definite-Lived Intangible Assets		$ 23,400
Weighted Average Amortization Life		15 years
Other intangible assets | Noveprim Group
Business Acquisition [Line Items]
Definite-Lived Intangible Assets	$ 9,500
Weighted Average Amortization Life	7 years
Other intangible assets | SAMDI Tech, Inc.
Business Acquisition [Line Items]
Definite-Lived Intangible Assets		$ 9,670
Weighted Average Amortization Life		7 years

v3.24.2.u1

REVENUE FROM CONTRACTS WITH CUSTOMERS - Schedule of Disaggregation of Revenues by Major Business Line (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 29, 2024	Jul. 01, 2023	Jun. 29, 2024	Jul. 01, 2023
Disaggregation of Revenue [Line Items]
Total revenue	$ 1,026,117	$ 1,059,937	$ 2,037,677	$ 2,089,310
RMS
Disaggregation of Revenue [Line Items]
Total revenue	206,389	209,948	427,296	409,714
RMS | Services and products transferred over time
Disaggregation of Revenue [Line Items]
Total revenue	95,299	94,458	192,348	188,097
RMS | Services and products transferred at a point in time
Disaggregation of Revenue [Line Items]
Total revenue	111,090	115,490	234,948	221,617
DSA
Disaggregation of Revenue [Line Items]
Total revenue	627,419	663,457	1,232,871	1,325,810
DSA | Services and products transferred over time
Disaggregation of Revenue [Line Items]
Total revenue	626,785	662,653	1,230,910	1,324,489
DSA | Services and products transferred at a point in time
Disaggregation of Revenue [Line Items]
Total revenue	634	804	1,961	1,321
Manufacturing
Disaggregation of Revenue [Line Items]
Total revenue	192,309	186,532	377,510	353,786
Manufacturing | Services and products transferred over time
Disaggregation of Revenue [Line Items]
Total revenue	104,481	100,460	204,539	186,546
Manufacturing | Services and products transferred at a point in time
Disaggregation of Revenue [Line Items]
Total revenue	$ 87,828	$ 86,072	$ 172,971	$ 167,240

v3.24.2.u1

REVENUE FROM CONTRACTS WITH CUSTOMERS - Schedule of Client Receivables, Contract Assets and Contract Liabilities (Details) - USD ($) $ in Thousands	Jun. 29, 2024	Dec. 30, 2023	Dec. 31, 2022
Revenue from Contract with Customer [Abstract]
Client receivables	$ 568,283	$ 578,077
Unbilled revenue	218,889	228,020	$ 204,000
Total	787,172	806,097
Less: Allowance for credit losses	(24,951)	(25,722)
Trade receivables and contract assets, net	762,221	780,375
Current deferred revenue	247,177	241,820
Long-term deferred revenue (included in Other long-term liabilities)	29,139	30,919
Customer contract deposits (included in Other current liabilities)	$ 92,032	$ 85,554

v3.24.2.u1

REVENUE FROM CONTRACTS WITH CUSTOMERS - Narrative (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 29, 2024	Jul. 01, 2023	Dec. 30, 2023	Dec. 31, 2022
Disaggregation of Revenue [Line Items]
Percentage of unbilled revenue billed during period	85.00%	85.00%
Unbilled revenue	$ 218,889		$ 228,020	$ 204,000
Percentage of contract liabilities recognized as revenue during period	70.00%	75.00%
Contract liabilities			273,000	$ 290,000
Unpaid advanced client billings	$ 46,000		$ 41,000
Net provision expense	4,100	$ 9,200
Performance obligations expected to be satisfied	$ 856,600
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-06-30
Disaggregation of Revenue [Line Items]
Revenue, remaining performance obligation, percentage	50.00%
Performance obligations expected to be satisfied, expected timing	12 months

v3.24.2.u1

REVENUE FROM CONTRACTS WITH CUSTOMERS - Schedule of Allowance for Credit Losses (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 29, 2024	Jul. 01, 2023
Accounts Receivable, Allowance for Credit Loss [Roll Forward]
Beginning balance	$ 25,722	$ 11,278
Provisions	4,719	9,849
Reductions	(5,490)	(3,087)
Ending balance	$ 24,951	$ 18,040

v3.24.2.u1

REVENUE FROM CONTRACTS WITH CUSTOMERS - Schedule of Lease Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 29, 2024	Jul. 01, 2023	Jun. 29, 2024	Jul. 01, 2023
Revenue from Contract with Customer [Abstract]
Lease revenue	$ 16,716	$ 23,891	$ 37,690	$ 47,981

v3.24.2.u1

SEGMENT AND GEOGRAPHIC INFORMATION - Schedule of Revenue and Other Financial Information by Reportable Segment (Details) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 29, 2024 USD ($)	Jul. 01, 2023 USD ($)	Jun. 29, 2024 USD ($) segment	Jul. 01, 2023 USD ($)
Segment Reporting [Abstract]
Number of reportable segments | segment			3
Segment Reporting Information [Line Items]
Revenue	$ 1,026,117	$ 1,059,937	$ 2,037,677	$ 2,089,310
Cost of revenue (excluding amortization of intangible assets)	672,404	660,960	1,339,121	1,312,679
Selling, general and administrative	169,791	199,758	356,082	374,604
Amortization of intangible assets	32,270	34,274	64,845	69,190
Operating income	151,652	164,945	277,629	332,837
Capital Expenditures	39,486	67,383	118,630	174,258
Depreciation and amortization	86,082	77,671	171,439	154,740
Unallocated corporate
Segment Reporting Information [Line Items]
Selling, general and administrative	53,902	69,914	119,594	115,968
Operating income	(53,902)	(69,914)	(119,594)	(115,968)
Capital Expenditures	146	702	1,425	1,571
Depreciation and amortization	1,742	1,075	3,382	2,121
RMS
Segment Reporting Information [Line Items]
Revenue	206,389	209,948	427,296	409,714
RMS | Operating Segments
Segment Reporting Information [Line Items]
Revenue	206,389	209,948	427,296	409,714
Cost of revenue (excluding amortization of intangible assets)	142,942	127,888	283,867	254,692
Selling, general and administrative	27,597	27,653	58,490	54,711
Amortization of intangible assets	5,902	5,489	11,842	10,984
Operating income	29,948	48,918	73,097	89,327
Capital Expenditures	9,313	7,493	29,357	26,577
Depreciation and amortization	16,538	13,949	34,661	27,438
DSA
Segment Reporting Information [Line Items]
Revenue	627,419	663,457	1,232,871	1,325,810
DSA | Operating Segments
Segment Reporting Information [Line Items]
Revenue	627,419	663,457	1,232,871	1,325,810
Cost of revenue (excluding amortization of intangible assets)	418,964	420,551	836,876	832,074
Selling, general and administrative	54,479	63,709	111,338	125,707
Amortization of intangible assets	15,600	17,659	31,442	35,060
Operating income	138,376	161,538	253,215	332,969
Capital Expenditures	19,444	48,326	68,403	113,510
Depreciation and amortization	47,729	43,124	93,518	85,574
Manufacturing
Segment Reporting Information [Line Items]
Revenue	192,309	186,532	377,510	353,786
Manufacturing | Operating Segments
Segment Reporting Information [Line Items]
Revenue	192,309	186,532	377,510	353,786
Cost of revenue (excluding amortization of intangible assets)	110,498	112,522	218,378	225,914
Selling, general and administrative	33,813	38,481	66,660	78,218
Amortization of intangible assets	10,768	11,126	21,561	23,145
Operating income	37,230	24,403	70,911	26,509
Capital Expenditures	10,583	10,862	19,445	32,600
Depreciation and amortization	$ 20,073	$ 19,523	$ 39,878	$ 39,607

v3.24.2.u1

SEGMENT AND GEOGRAPHIC INFORMATION - Schedule of Revenue and Long-Lived Assets by Geographic Segment (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 29, 2024	Jul. 01, 2023	Jun. 29, 2024	Jul. 01, 2023	Dec. 30, 2023
Segment Reporting Information [Line Items]
Revenue	$ 1,026,117	$ 1,059,937	$ 2,037,677	$ 2,089,310
Long-lived assets	1,613,895		1,613,895		$ 1,639,741
U.S.
Segment Reporting Information [Line Items]
Revenue	571,427	606,775	1,133,744	1,212,216
Long-lived assets	950,254		950,254		964,176
Europe
Segment Reporting Information [Line Items]
Revenue	271,377	272,976	547,696	540,679
Long-lived assets	405,429		405,429		407,375
Canada
Segment Reporting Information [Line Items]
Revenue	125,244	117,647	235,645	228,253
Long-lived assets	153,945		153,945		157,483
Asia Pacific
Segment Reporting Information [Line Items]
Revenue	50,387	59,864	96,159	102,677
Long-lived assets	68,868		68,868		74,605
Other
Segment Reporting Information [Line Items]
Revenue	7,682	$ 2,675	24,433	$ 5,485
Long-lived assets	$ 35,399		$ 35,399		$ 36,102

v3.24.2.u1

SUPPLEMENTAL CASH FLOW INFORMATION - Schedule of Non-Cash Investing Activities (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 29, 2024	Jul. 01, 2023
Supplemental Cash Flow Information [Abstract]
Cash paid for income taxes	$ 71,722	$ 61,816
Cash paid for interest	65,630	66,563
Purchases of Property, plant and equipment included in Accounts payable and Accrued liabilities	25,278	47,850
Assets acquired under finance leases	$ 3,159	$ 154

v3.24.2.u1

SUPPLEMENTAL CASH FLOW INFORMATION - Schedule of Cash, Cash Equivalents and Restricted Cash (Details) - USD ($) $ in Thousands	Jun. 29, 2024	Dec. 30, 2023	Jul. 01, 2023	Dec. 31, 2022
Supplemental Cash Flow Information [Abstract]
Cash and cash equivalents	$ 179,213	$ 276,771
Restricted cash included in Other current assets	325	5,803
Restricted cash included in Other assets	1,466	1,906
Cash, cash equivalents, and restricted cash, end of period	$ 181,004	$ 284,480	$ 208,777	$ 241,214

v3.24.2.u1

INVENTORY (Details) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 29, 2024	Jun. 29, 2024	Dec. 30, 2023
Inventory Disclosure [Abstract]
Raw materials and supplies	$ 43,238	$ 43,238	$ 42,296
Work in process	57,923	57,923	59,727
Finished products	247,950	247,950	278,236
Inventories	349,111	349,111	$ 380,259
Amortization of inventory step up	$ 3,500	$ 10,600

v3.24.2.u1

PROPERTY, PLANT AND EQUIPMENT, NET (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 29, 2024	Jul. 01, 2023	Jun. 29, 2024	Jul. 01, 2023	Dec. 30, 2023
Property, Plant and Equipment [Line Items]
Total	$ 3,011,230		$ 3,011,230		$ 2,975,050
Less: Accumulated depreciation	(1,397,335)		(1,397,335)		(1,335,309)
Property, plant and equipment, net	1,613,895		1,613,895		1,639,741
Depreciation	47,600	$ 43,400	93,300	$ 85,500
Land
Property, Plant and Equipment [Line Items]
Total	78,812		78,812		79,546
Buildings
Property, Plant and Equipment [Line Items]
Total	1,061,408		1,061,408		1,053,915
Machinery and equipment
Property, Plant and Equipment [Line Items]
Total	1,007,210		1,007,210		984,867
Leasehold improvements
Property, Plant and Equipment [Line Items]
Total	381,879		381,879		366,556
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Total	32,060		32,060		31,284
Computer hardware and software
Property, Plant and Equipment [Line Items]
Total	259,889		259,889		254,413
Vehicles
Property, Plant and Equipment [Line Items]
Total	7,149		7,149		6,746
Construction in progress
Property, Plant and Equipment [Line Items]
Total	$ 182,823		$ 182,823		$ 197,723

v3.24.2.u1

VENTURE CAPITAL AND STRATEGIC EQUITY INVESTMENTS (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 29, 2024	Jul. 01, 2023
Schedule of Equity Method Investments [Roll Forward]
Beginning balance	$ 243,811
Ending balance	231,859
Venture Capital Funds
Schedule of Equity Method Investments [Roll Forward]
Beginning balance	121,158	$ 129,012
Capital contributions	6,479	8,702
Distributions	(16,100)	(9,679)
Gains (losses)	1,789	(8,429)
Foreign currency translation	(249)	466
Ending balance	113,077	120,072
Strategic Investments
Schedule of Equity Method Investments [Roll Forward]
Beginning balance	122,653	182,590
Purchase of investments	2,140	13,710
Distributions	0	(4,146)
Gains (losses)	(5,265)	3,253
Reduction for acquisition of entity	0	(12,635)
Foreign currency translation	(746)	(2,563)
Ending balance	$ 118,782	$ 180,209

v3.24.2.u1

FAIR VALUE - Schedule of Fair Value of Assets and Liabilities (Details) - Fair Value, Recurring - USD ($) $ in Thousands	Jun. 29, 2024	Dec. 30, 2023
Current assets measured at fair value:
Cash equivalents	$ 7,257	$ 29
Term deposit	26,983
Other assets:
Life insurance policies	45,210	40,912
Interest rate swap	1,338	966
Total assets measured at fair value	80,788	41,907
Other long-term liabilities measured at fair value:
Contingent consideration	38,335	33,265
Total liabilities measured at fair value	38,335	33,265
Level 1
Current assets measured at fair value:
Cash equivalents	0	0
Term deposit	0
Other assets:
Life insurance policies	0	0
Interest rate swap	0	0
Total assets measured at fair value	0	0
Other long-term liabilities measured at fair value:
Contingent consideration	0	0
Total liabilities measured at fair value	0	0
Level 2
Current assets measured at fair value:
Cash equivalents	7,257	29
Term deposit	26,983
Other assets:
Life insurance policies	45,210	40,912
Interest rate swap	1,338	966
Total assets measured at fair value	80,788	41,907
Other long-term liabilities measured at fair value:
Contingent consideration	0	0
Total liabilities measured at fair value	0	0
Level 3
Current assets measured at fair value:
Cash equivalents	0	0
Term deposit	0
Other assets:
Life insurance policies	0	0
Interest rate swap	0	0
Total assets measured at fair value	0	0
Other long-term liabilities measured at fair value:
Contingent consideration	38,335	33,265
Total liabilities measured at fair value	$ 38,335	$ 33,265

v3.24.2.u1

FAIR VALUE - Schedule of Contingent Consideration (Details) - Contingent Consideration - Level 3 - USD ($) $ in Thousands	6 Months Ended
	Jun. 29, 2024	Jul. 01, 2023
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	$ 33,265	$ 13,431
Payments	0	(15,130)
Adjustment of previously recorded contingent liability	5,070	1,810
Foreign currency translation	0	(111)
Ending balance	$ 38,335	$ 0

v3.24.2.u1

FAIR VALUE - Narrative (Details) - USD ($) $ in Thousands	Jun. 29, 2024	Dec. 30, 2023	Jul. 01, 2023	Dec. 31, 2022
Designated as Hedging Instrument | Interest Rate Swap
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Notional amount	$ 500,000
Derivative, fixed interest rate	4.65%
Level 3 | Contingent Consideration
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of contingent consideration	$ 38,335	$ 33,265	$ 0	$ 13,431
Weighted average probability percentage of achieving maximum target	70.00%
Level 3 | Average Volatility | Contingent Consideration
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration, measurement input	0.05
Level 3 | Weighted Average Cost of Capital | Contingent Consideration
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration, measurement input	0.08
Level 3 | Maximum | Contingent Consideration
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of contingent consideration	$ 55,000

v3.24.2.u1

FAIR VALUE - Schedule of Fair Value of Debt (Details) - Senior Notes - USD ($) $ in Thousands	Jun. 29, 2024	Dec. 30, 2023
4.25% Senior Notes due 2028
Debt Instrument [Line Items]
Stated interest rate	4.25%	4.25%
4.25% Senior Notes due 2028 | Book Value
Debt Instrument [Line Items]
Debt instrument value	$ 500,000	$ 500,000
4.25% Senior Notes due 2028 | Fair Value
Debt Instrument [Line Items]
Debt instrument value	$ 468,750	$ 478,100
3.75% Senior Notes due 2029
Debt Instrument [Line Items]
Stated interest rate	3.75%	3.75%
3.75% Senior Notes due 2029 | Book Value
Debt Instrument [Line Items]
Debt instrument value	$ 500,000	$ 500,000
3.75% Senior Notes due 2029 | Fair Value
Debt Instrument [Line Items]
Debt instrument value	$ 453,750	$ 458,100
4.00% Senior Notes due 2031
Debt Instrument [Line Items]
Stated interest rate	4.00%	4.00%
4.00% Senior Notes due 2031 | Book Value
Debt Instrument [Line Items]
Debt instrument value	$ 500,000	$ 500,000
4.00% Senior Notes due 2031 | Fair Value
Debt Instrument [Line Items]
Debt instrument value	$ 445,000	$ 449,350

v3.24.2.u1

GOODWILL AND INTANGIBLE ASSETS - Schedule of Rollforward of Goodwill (Details) $ in Thousands	6 Months Ended
	Jun. 29, 2024 USD ($)
Goodwill [Roll Forward]
Beginning balance	$ 3,095,045
Acquisitions	17,675
Foreign exchange	(33,027)
Ending balance	3,079,693
RMS
Goodwill [Roll Forward]
Beginning balance	497,474
Acquisitions	0
Foreign exchange	(536)
Ending balance	496,938
DSA
Goodwill [Roll Forward]
Beginning balance	1,662,434
Acquisitions	17,675
Foreign exchange	(29,251)
Ending balance	1,650,858
Goodwill, impaired, accumulated impairment loss	1,000,000
Manufacturing
Goodwill [Roll Forward]
Beginning balance	935,137
Acquisitions	0
Foreign exchange	(3,240)
Ending balance	$ 931,897

v3.24.2.u1

GOODWILL AND INTANGIBLE ASSETS - Schedule of Intangible Assets (Details) - USD ($) $ in Thousands	Jun. 29, 2024	Dec. 30, 2023
Other intangible assets
Gross	$ 1,716,746	$ 1,729,559
Accumulated Amortization	(916,617)	(865,508)
Net	800,129	864,051
Client relationships
Other intangible assets
Gross	1,518,194	1,528,780
Accumulated Amortization	(766,261)	(721,322)
Net	751,933	807,458
Technology
Other intangible assets
Gross	140,737	142,190
Accumulated Amortization	(114,410)	(111,764)
Net	26,327	30,426
Trademarks and trade names
Other intangible assets
Gross	11,849	11,878
Accumulated Amortization	(5,098)	(4,568)
Net	6,751	7,310
Backlog
Other intangible assets
Gross	3,100	3,100
Accumulated Amortization	(2,792)	(2,177)
Net	308	923
Other
Other intangible assets
Gross	42,866	43,611
Accumulated Amortization	(28,056)	(25,677)
Net	$ 14,810	$ 17,934

v3.24.2.u1

GOODWILL AND INTANGIBLE ASSETS - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 29, 2024	Jul. 01, 2023	Jun. 29, 2024	Jul. 01, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization of intangible assets	$ 32,270	$ 34,274	$ 64,845	$ 69,190

v3.24.2.u1

DEBT AND OTHER FINANCING ARRANGEMENTS - Schedule of Long-Term Debt (Details) - USD ($) $ in Thousands	Jun. 29, 2024	Dec. 30, 2023
Debt Instrument [Line Items]
Finance leases	$ 29,637	$ 28,550
Total debt and finance leases	2,425,260	2,667,368
Current portion of long-term debt	435	3,172
Current portion of finance leases	2,778	2,398
Current portion of long-term debt and finance leases	3,213	5,570
Long-term debt and finance leases	2,422,047	2,661,798
Debt discount and debt issuance costs	(12,667)	(14,651)
Long-term debt, net and finance leases	2,409,380	2,647,147
Revolving Facility
Debt Instrument [Line Items]
Long-term debt, gross	$ 879,498	$ 1,129,243
Senior Notes | 4.25% Senior Notes due 2028
Debt Instrument [Line Items]
Stated interest rate	4.25%	4.25%
Long-term debt, gross	$ 500,000	$ 500,000
Senior Notes | 3.75% Senior Notes due 2029
Debt Instrument [Line Items]
Stated interest rate	3.75%	3.75%
Long-term debt, gross	$ 500,000	$ 500,000
Senior Notes | 4.00% Senior Notes due 2031
Debt Instrument [Line Items]
Stated interest rate	4.00%	4.00%
Long-term debt, gross	$ 500,000	$ 500,000
Other Debt
Debt Instrument [Line Items]
Long-term debt, gross	$ 16,125	$ 9,575

v3.24.2.u1

DEBT AND OTHER FINANCING ARRANGEMENTS - Narrative (Details) - USD ($) $ in Millions	Jun. 29, 2024	Dec. 30, 2023
Debt Instrument [Line Items]
Weighted average interest rate	4.64%	4.93%
Letter of Credit
Debt Instrument [Line Items]
Letters of credit outstanding	$ 21.2	$ 21.6

v3.24.2.u1

EQUITY AND NONCONTROLLING INTERESTS - Schedule of Earnings Per Share (Details) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 29, 2024	Jul. 01, 2023	Jun. 29, 2024	Jul. 01, 2023
Numerator:
Net income	$ 94,261	$ 99,443	$ 168,743	$ 203,397
Less: Net income attributable to noncontrolling interests	180	2,423	1,702	3,246
Net income available to Charles River Laboratories International, Inc.	94,081	97,020	167,041	200,151
Calculation of net income per share attributable to common shareholders of Charles River Laboratories International, Inc.
Net income available to Charles River Laboratories International, Inc.	94,081	97,020	167,041	200,151
Less: Adjustment of redeemable noncontrolling interest	301	0	702	0
Less: Incremental dividends attributable to noncontrolling interest holders	3,792	0	9,022	0
Net income available to Charles River Laboratories International, Inc. common shareholders	$ 89,988	$ 97,020	$ 157,317	$ 200,151
Denominator:
Weighted-average shares outstanding - Basic (in shares)	51,551	51,216	51,494	51,157
Effect of dilutive securities:
Stock options, restricted stock units and performance share units (in shares)	295	251	316	225
Weighted-average shares outstanding - Diluted (in shares)	51,846	51,467	51,810	51,382
Anti-dilutive common stock equivalents (in shares)	506	594	482	589

v3.24.2.u1

EQUITY AND NONCONTROLLING INTERESTS - Narrative (Details) - USD ($) shares in Millions	6 Months Ended
	Jun. 29, 2024	Jul. 01, 2023	Aug. 02, 2024
Treasury Shares and Accelerated Stock Repurchase Program (ASR) [Line Items]
Shares acquired to satisfy minimum individual statutory tax withholdings for vesting of equity instruments (in shares)	0.1	0.1
Shares acquired to satisfy minimum individual statutory tax withholdings for vesting of equity instruments	$ 18,300,000	$ 24,000,000.0
Authorized Share Repurchase Program
Treasury Shares and Accelerated Stock Repurchase Program (ASR) [Line Items]
Aggregate authorization of share repurchase program	1,300,000,000
Remaining authorized repurchase amount	$ 129,100,000
New Stock Repurchase Authorization | Subsequent Event
Treasury Shares and Accelerated Stock Repurchase Program (ASR) [Line Items]
Aggregate authorization of share repurchase program			$ 1,000,000,000

v3.24.2.u1

EQUITY AND NONCONTROLLING INTERESTS - Schedule of Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 29, 2024	Jul. 01, 2023	Jun. 29, 2024	Jul. 01, 2023
Accumulated Other Comprehensive Income (Loss), before Tax [Roll Forward]
Beginning balance	$ 3,646,150	$ 3,113,883	$ 3,602,276	$ 2,981,078
Income tax expense (benefit)	(2,027)	937	(7,500)	(101)
Ending balance	3,727,018	3,257,555	3,727,018	3,257,555
Foreign Currency Translation Adjustment and Other
Accumulated Other Comprehensive Income (Loss), before Tax [Roll Forward]
Beginning balance			(149,999)
Other comprehensive income (loss) before reclassifications			(81,840)
Net current period other comprehensive income (loss)			(81,840)
Income tax expense (benefit)			(7,759)
Ending balance	(224,080)		(224,080)
Pension and Other Post-Retirement Benefit Plans
Accumulated Other Comprehensive Income (Loss), before Tax [Roll Forward]
Beginning balance			(47,167)
Other comprehensive income (loss) before reclassifications			686
Net current period other comprehensive income (loss)			686
Income tax expense (benefit)			170
Ending balance	(46,651)		(46,651)
Net Unrealized (Loss) Gain on Cash Flow Hedge
Accumulated Other Comprehensive Income (Loss), before Tax [Roll Forward]
Beginning balance			739
Other comprehensive income (loss) before reclassifications			372
Net current period other comprehensive income (loss)			372
Income tax expense (benefit)			89
Ending balance	1,022		1,022
Total
Accumulated Other Comprehensive Income (Loss), before Tax [Roll Forward]
Beginning balance	(249,919)	(239,124)	(196,427)	(262,057)
Other comprehensive income (loss) before reclassifications			(80,782)
Net current period other comprehensive income (loss)			(80,782)
Income tax expense (benefit)			(7,500)
Ending balance	$ (269,709)	$ (208,269)	$ (269,709)	$ (208,269)

v3.24.2.u1

EQUITY AND NONCONTROLLING INTERESTS - Nonredeemable and Redeemable Noncontrolling Interest - Narrative (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended				6 Months Ended
	Jun. 30, 2022	Jun. 29, 2024	Mar. 30, 2024	Dec. 30, 2023	Jul. 01, 2023	Jun. 29, 2024	Jul. 01, 2023	Nov. 30, 2023	Dec. 31, 2022	Dec. 28, 2019
Schedule of Investments [Line Items]
Incremental dividends attributed to noncontrolling interest holders		$ 3,792			$ 0	$ 9,022	$ 0
Adjustment of redeemable noncontrolling interests to redemption value		496	$ 4,807
Additional Paid-In Capital
Schedule of Investments [Line Items]
Adjustment of redeemable noncontrolling interests to redemption value		195	4,406
Retained Earnings
Schedule of Investments [Line Items]
Adjustment of redeemable noncontrolling interests to redemption value		$ 301	401
Noveprim Group
Schedule of Investments [Line Items]
Percentage of voting interests acquired								41.00%
Noveprim Group
Schedule of Investments [Line Items]
Equity interest		90.00%				90.00%
Noncontrolling interest ownership percentage		10.00%				10.00%
Contractually defined redemption value		$ 46,100				$ 46,100
Dividend fair value		8,000				8,000
Incremental dividends attributed to noncontrolling interest holders						9,000
Noveprim Group | Additional Paid-In Capital
Schedule of Investments [Line Items]
Adjustment of redeemable noncontrolling interests to redemption value						1,800
Noveprim Group | Retained Earnings
Schedule of Investments [Line Items]
Adjustment of redeemable noncontrolling interests to redemption value						700
Noveprim Group | Minimum
Schedule of Investments [Line Items]
Contractually defined redemption value		47,000				47,000
Noveprim Group | Maximum
Schedule of Investments [Line Items]
Contractually defined redemption value		54,000				$ 54,000
Supplier
Schedule of Investments [Line Items]
Equity interest										80.00%
Noncontrolling interest ownership percentage	10.00%									20.00%
Contractually defined redemption value			12,000
Additional ownership percentage acquired by parent	10.00%
Purchase of additional equity interest	$ 15,000	$ 12,000
Supplier | Additional Paid-In Capital
Schedule of Investments [Line Items]
Adjustment of redeemable noncontrolling interests to redemption value			$ 2,800
Vital River
Schedule of Investments [Line Items]
Equity interest									92.00%
Noncontrolling interest ownership percentage				8.00%
Payments for repurchase of redeemable noncontrolling interest				$ 4,800
Redeemable noncontrolling interest, purchase price payable				$ 24,400

v3.24.2.u1

INCOME TAXES - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 29, 2024	Jul. 01, 2023	Jun. 29, 2024	Jul. 01, 2023
Income Tax Disclosure [Abstract]
Effective tax rate	21.20%	22.70%	22.80%	21.70%
Increase in unrecognized tax benefits	$ 0.6
Unrecognized tax benefits	24.0		$ 24.0
Increase in unrecognized tax benefits that would impact effective tax rate	0.4
Unrecognized tax benefits that would impact effective tax rate	21.1		21.1
Accrued interest on unrecognized tax benefits	1.6		1.6
Decrease in unrecognized tax benefits that are reasonably possibly over the next twelve-month period	$ 5.0		$ 5.0

v3.24.2.u1

INCOME TAXES - Schedule of Prepaid and Accrued Tax Positions (Details) - USD ($) $ in Thousands	Jun. 29, 2024	Dec. 30, 2023
Income Tax Disclosure [Abstract]
Prepaid income tax	$ 71,242	$ 59,715
Accrued income taxes	$ 35,126	$ 38,819

v3.24.2.u1

RESTRUCTURING AND ASSET IMPAIRMENTS - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 29, 2024	Jul. 01, 2023	Jun. 29, 2024	Jul. 01, 2023	Dec. 30, 2023	Dec. 31, 2022
Segment Reporting Information [Line Items]
Restructuring charges	$ 17,955	$ 2,699	$ 34,954	$ 6,185
Restructuring and related cost, cost incurred	65,000		65,000
Restructuring reserve	10,604	3,901	10,604	3,901	$ 5,050	$ 1,300
Severance and Transition Costs
Segment Reporting Information [Line Items]
Restructuring charges			14,934	3,431
Restructuring reserve	9,729	$ 2,985	9,729	$ 2,985	4,175	$ 356
Accrued Compensation | Severance and Transition Costs
Segment Reporting Information [Line Items]
Restructuring reserve	$ 10,600		$ 10,600		$ 5,100

v3.24.2.u1

RESTRUCTURING AND ASSET IMPAIRMENTS - Schedule of Restructuring Costs by Reportable Segment (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 29, 2024	Jul. 01, 2023	Jun. 29, 2024	Jul. 01, 2023
Segment Reporting Information [Line Items]
Total	$ 17,955	$ 2,699	$ 34,954	$ 6,185
Operating Segments | RMS
Segment Reporting Information [Line Items]
Total	10,228	0	17,615	0
Operating Segments | DSA
Segment Reporting Information [Line Items]
Total	3,766	0	10,257	(2)
Operating Segments | Manufacturing
Segment Reporting Information [Line Items]
Total	2,657	2,699	4,288	6,187
Unallocated corporate
Segment Reporting Information [Line Items]
Total	$ 1,304	$ 0	$ 2,794	$ 0

v3.24.2.u1

RESTRUCTURING AND ASSET IMPAIRMENTS - Schedule of Restructuring Costs for Productivity Improvement (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 29, 2024	Jul. 01, 2023	Jun. 29, 2024	Jul. 01, 2023
Restructuring Cost and Reserve [Line Items]
Severance and Transition Costs	$ 5,897	$ 2,517	$ 14,934	$ 3,431
Asset Impairments and Other Costs	12,058	182	20,020	2,754
Total	17,955	2,699	34,954	6,185
Cost of services provided (excluding amortization of intangible assets)
Restructuring Cost and Reserve [Line Items]
Severance and Transition Costs	2,870	2,361	7,680	2,928
Asset Impairments and Other Costs	1,926	0	3,034	0
Total	4,796	2,361	10,714	2,928
Cost of products sold (excluding amortization of intangible assets)
Restructuring Cost and Reserve [Line Items]
Severance and Transition Costs	69	36	747	54
Asset Impairments and Other Costs	9,154	182	10,484	2,746
Total	9,223	218	11,231	2,800
Selling, general and administrative
Restructuring Cost and Reserve [Line Items]
Severance and Transition Costs	2,958	120	6,507	449
Asset Impairments and Other Costs	978	0	6,502	8
Total	$ 3,936	$ 120	$ 13,009	$ 457

v3.24.2.u1

RESTRUCTURING AND ASSET IMPAIRMENTS - Schedule of Rollforward of Severance and Transition and Lease Obligation Liabilities (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 29, 2024	Jul. 01, 2023	Jun. 29, 2024	Jul. 01, 2023
Restructuring Reserve [Roll Forward]
Beginning balance			$ 5,050	$ 1,300
Expense	$ 17,955	$ 2,699	34,954	6,185
Payments / utilization			(14,390)	(1,114)
Other non-cash adjustments			(14,953)	(2,479)
Foreign currency adjustments			(57)	9
Ending Balance	10,604	3,901	10,604	3,901
Severance and Transition Costs
Restructuring Reserve [Roll Forward]
Beginning balance			4,175	356
Expense			14,934	3,431
Payments / utilization			(9,323)	(811)
Other non-cash adjustments			0	0
Foreign currency adjustments			(57)	9
Ending Balance	9,729	2,985	9,729	2,985
Asset Impairments
Restructuring Reserve [Roll Forward]
Beginning balance			0	0
Expense			14,181	2,479
Payments / utilization			0	0
Other non-cash adjustments			(14,181)	(2,479)
Foreign currency adjustments			0	0
Ending Balance	0	0	0	0
Other Costs
Restructuring Reserve [Roll Forward]
Beginning balance			875	944
Expense			5,839	275
Payments / utilization			(5,067)	(303)
Other non-cash adjustments			(772)	0
Foreign currency adjustments			0	0
Ending Balance	$ 875	$ 916	$ 875	$ 916

v3.24.2.u1

COMMITMENTS AND CONTINGENCIES (Details) $ in Millions	Jun. 29, 2024 USD ($)
US Fish and Wildlife Service | Pending Litigation
Loss Contingencies [Line Items]
Inventory, non-human primates	$ 27

---